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Chapter 1
Introduction

Genes and mechanisms in primary 
microcephaly
Introduction 
Intellectual disability and other neurological diseases in childhood often 
result from congenital disorders, some being caused by genetic mutations, 
following Mendelian and non-mendelian (multifactorial) inheritance. 
Congenital disorders of the brain are sometimes recognizable at birth and 
affect the structure of the brain and or the head size. One of these disorders 
is congenital microcephaly, the topic of this thesis. In order to introduce the 
experimental work I will review the concept and defi nition, illustrate the 
importance of studying this topic for the understanding of human brain 
evolution and present the current hypothesis about disease pathogenesis.
Defi nition and Prevalence
Microcephaly is defi ned as a head circumference smaller than 3 standard 
deviation (SD) when corrected for age and sex. The prevalence of micro-
cephaly, which is diffi cult to ascertain and is dependent on the threshold 
used, is estimated to be between 1 and 2.5 % of the adult population (Ul-
ster University data 2003). The prevalence of microcephaly in neurodevel-
opmental clinic is on average 25%1. 
Microcephaly can be present at birth (primary or congenital) or become 
evident in the years after birth (acquired or secondary).
Congenital microcephaly has an incidence of approximately 1.6 per 10 000 
births (Ulster University data 2003) in the UK. Congenital microcephaly 
can be further subdivided into syndromic microcephaly and non-syndromic 
(isolated) microcephaly.
Syndromic microcephaly, i.e. microcephaly with additional features, can 
be divided based on aetiology into non-genetic and genetic causes. 
Non-genetic causes include environmental insults such as exposure to 
alcohol (foetal alcohol spectrum disorder), radiation, toxins or congenital 
infections, (e.g. CMV, toxoplasmosis, HIV, rubella) and, rarely, maternal 
metabolic disorders e.g. maternal PKU. 
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Syndromic genetic causes of congenital microcephaly can be further 
subdivided dependent on where the defect lies: numeric or structural 
chromosomal abnormalities or single gene defects.
Examples of numerical chromosomal abnormalities include trisomy 21 
(Down), trisomy 18 and trisomy 13. Examples of structural anomalies 
detected at routine karyotyping are deletion syndromes; such as 4p or 5p 
deletion syndrome. Examples of submicroscopic abnormalities detected 
at microarray analysis are 5q14.3 microdeletion2 or 1q43q443. In these 
cases multiple genes are involved in the deletion, but in some cases 
single genes in the area are considered responsible of the phenotype. The 
non-chromosomal and monogenetic causes of primary microcephaly are 
very heterogeneous. A search on the London Medical Database (LMD), 
to include microcephaly, brings up 758 items. Only a few inborn errors 
of metabolism are classifi ed as cause of primary microcephaly, such as 
serine biosynthesis defects and sulphite oxidase/molybdenum cofactor 
defi ciency4. 
Non syndromic microcephaly, as isolated monogenetic microcephaly, 
is also called “microcephaly vera”. Microcephalia vera is defi ned by 1) 
congenital microcephaly of > 3 SD below the age related mean, without 
craniosynostosis; 2) absence of associated malformations; 3) absence 
of environmental causes; 4) non-progressive mental retardation (usually 
mild to moderate), but no other abnormal neurological fi ndings; 5) the 
presence of seizures does not exclude the diagnosis5. This type of primary 
microcephaly is also indicated as MCPH, and its inheritance is autosomal 
recessive with nine genes/loci known to be involved until now6. 
The brain morphology in this disorder, as studied at MRI or post-mortem 
specimens, shows normal or simplifi ed gyration and usually normal or thin 
brain cortex. The cerebellum can be normal or slightly underdeveloped7,8,9. 
This thesis will concentrate on the monogenetic causes of syndromic 
primary microcephaly and mechanisms leading to this brain malformation.
Evolution
Cortical size is regulated by a balance between neuroproliferation and 
apoptosis10. Over the last 3 million years a feature of primate evolution has 
been a 3 times increase in brain size, especially the neocortex11 and a 100 
times increase in gyration along with an increase in cognitive function12. As 
brain size and gyration are correlated with number of neurons it is logical 
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to look at genes that control proliferation and/ or apoptosis in order to 
understand the genetic basis of these changes. Therefore the MCPH genes 
are seen as instrumental to the elucidation of mechanisms regulating brain 
size and cortical development. 
Studies have suggested that the MCPH genes ASPM (abnormal spindle-
like microcephaly-associated MIM:608176) and CDK5RAP2 (CDK5 
regulatory subunit associated protein 2 MIM:608201) are subject to 
positive selection for an evolution of increase in brain size over anthropoid 
primates13. ASPM is one of the genes most often mutated in patients with 
primary microcephaly8,14. In ASPM affected individuals there is a decrease 
in cortical size but not whole brain or cerebellum size8. Philogenetic analysis 
of ASPM and its Drosophila melanogaster homolog abnormal spindle (Asp) 
have shown the main difference between fl ies and humans is the large 
single insertion coding for a so-called “IQ” (isoleucine-glutamine) domain8. 
Gorilla and human lineages show particularly accelerated evolution 
in this domain15. This is consistent with the effect of mitotic spindle on 
neurogenesis and expression patterns of ASPM which is highly expressed 
in cerebral cortex8. Although known primary microcephaly genes are good 
candidates and are probably contributing factors, the genetic contribution 
to evolution of cortical size is largely unknown and it is also unclear which 
selection pressures are involved. 
Embryonic Development and neuroproliferation
In order for the brain to develop normally there needs to be rapid and 
continuous cellular proliferation from the rostral end of the foetal neural 
tube. A correct balance is required between neural progenitor proliferation 
and differentiation for normal brain development and brain size16 which 
occurs on the ventricular surface. In the ventricular zone the cells undergo 
symmetric (to produce progenitor cells and expand the progenitor pool) and 
asymmetrical division (to produce one progenitor and one cell that migrates 
out of the ventricular zone and differentiates into a neuron). This results in 
increasing number of neurons and cortical thickness. The balance between 
symmetrical and asymmetrical division changes over time (initially greater 
symmetrical division changing to an increased asymmetrical division) in 
order for the correct amount of neurons to be produced17. This is at least 
partially determined by the plane of the mitotic spindle. Vertical cleavage 
leads to division of the progenitor cell into two identical progenitor daughter 
cells, horizontal cleavage results in asymmetric division into an apical and 
a basal daughter cell to return to the progenitor pool. The other daughter 
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becomes post- mitotic and differentiates at the pial surface to become 
neuron (Figure 1)18.
Figure 1. In early cortical development most divisions are in the vertical cleavage plane 
(lower panel) to give two identical or symmetrical daughter progenitor cell. In later cortical 
development the cleavage plane changes to become horizontal and give a progenitor and 
a neuron. This is dependent on the position of the centrosome and mitotic spindle in order 
to create the correct amounts of neurons and progenitor pool. 
The mitotic spindle orientation is directed by the centrosome location. 
Centrosomes are the main cytoplasmic microtubule organising centre 
(MTOC) in animal cells; they have a vital role in cell polarity, cell cycle 
control and cell division. The centrosome is composed of two centrioles 
surrounded by peri-centriolar material (PCM). During the cell cycle in 
G1 there are two centrioles in the PCM, at the beginning of the S phase 
a single pro-centriole forms next to the parent centriole. These two 
elongate so at the beginning of mitosis two centrosomes are present 
which anchor microtubules and form the poles of the mitotic spindle and 
tightly regulate chromosome numbers. Centrosomes are also integral to 
biosynthesis of cilia as the cilliary basal body is derived from centrioles 
in order to establish the axoneme. Centrosome abnormalities lead to 
abnormal mitotic spindle and thus abnormal cell proliferation. Centrosome 
abnormalities were fi rst linked to cancer as centrosome amplifi cation 
can lead to chromosome instability, multiple cilia and neuroblast over 
proliferation19. After this discovery, centrosomes were then linked 
to a variety of human diseases including brain development and 
ciliopathies20. Although the whole process is not completely understood it 
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is clear that, besides centrosomes, also other mitotic spindle proteins are 
essential for this process21. It has been hypothesized that if this process 
is disturbed then neuronal proliferation would be decreased and thus 
cause microcephaly8,22,23. In support of this reasoning is that all of the 
described MCPH genes and some genes that cause Seckel syndrome 
(a syndromic primary microcephaly) encode for proteins important in 
the centrosome or mitotic spindle and all are expressed in the neuro-
epithelium during embryonic neurogenesis22,23.
The post mitotic neurons produced by asymmetrical division migrate to 
their target area by radial migration to form the six layers of the cortex. 
This occurs with the fi rst neurons making up the innermost layer and later 
neurons subsequently making up the outer layers to form the cortex in 
an inside-out fashion17,24. Disturbances in this process lead to cortical 
malformations/migration disorders such as the lissencephalies. 
Primary microcephalies present with an apparently normal (or thin) cortex 
with a decreased number of convolutions, this is usually referred to as 
simplifi ed gyration. However in primary microcephalies the process of 
convolution can be abnormal and the small brain can associated with 
a different sort of malformations such as lissencephaly. This is often 
referred to as micro-lissencephaly, as seen in biallelic NDE1 (MIM:614019) 
mutations25,26. In other examples, the microcephaly is associated with 
abnormal convolution, presenting multiple and shallow gyri with fusion 
of the gyri, typical of polymicrogyria, as seen in several individuals with 
WDR62 (WD repeat-containing protein 62 MIM:613583) mutations27.
Apoptosis and cortical development
In studies of development of the human neo-cortex it has been found 
that in the areas of proliferation from week 5 of development28 there is 
programmed cell death or “apoptosis” present. Over the next weeks the 
rate of apoptosis increases and spreads throughout the cortical layers 
but is highest in the ventricular and subventricular zone28. Apoptosis is 
a complex multi step, multi pathway cell death program which is under 
complex genetic control, it is the end point of a number of pathways and 
can be triggered by extra cellular factors such as UV irradiation, or intra-
cellular causes such as endoplasmic reticulum (ER) stress, DNA damage 
and tumour necrosis factor (TNF) pathways29,30.
The fi nal common pathway in apoptosis from all causes is activation of 
the caspase cascade. Pro-caspases are cleaved and become active, 
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these then cleave further pro-caspases in an amplifying reaction and 
activate further proteins that dismantle the nucleus and DNA and result 
in death of the cell. Studies in mice show that apoptotic death is essential 
for determination of the cerebral cortex size31. Caspase defi cient mice 
(casp 9 -/-) show hyperplasia of the mouse forebrain. I.e. in animals with 
a decreased functioning apoptotic pathway the brain size increased32. It 
could therefore be reasoned that mammals with increased apoptosis could 
have microcephaly. The evidence for deranged apoptotic control causing 
microcephaly is scarce but has been proposed as a mechanism in several 
disorders including the DNA repair disorders33.
Classifi cation of primary Microcephaly 
The most widely used classifi cation system for malformations of cortical 
development, as detected by brain MRI, is designed by James Barkovich 
and collaborators34. Initially in 2001 this was based on a radiological 
classifi cation35. However, due to an increase in knowledge regarding 
mechanisms and genetic causes, the most recent update is based on 
a mixture of MRI fi ndings, genetic and clinical information34. Congenital 
microcephaly falls into the “Barkovich’s” group I (within the disorders 
of neural proliferation or apoptosis) and III (within the disorders of 
postmigrational development). However, some patients will cross over 
several groups. 
Group I A includes malformations secondary to abnormal neuronal and glial 
proliferation or apoptosis. This includes the microcephaly with a normal, or 
thin cortex, and simplifi ed gyration, due to mutations in the MCPH genes 
and other centrosomal genes that cause the large group of syndromic 
primordial dwarfi sm. There are no defi nable radiological characteristics 
that can separate out the primary microcephalies. This radiological aspect 
of this group is often indicated as MSG, i.e. microcephaly with simplifi ed 
gyration9.
The mutations in genes involved in migrational development such as NDE1, 
TBR2 (T-box brain 2 MIM: 604615) and WDR62 are also included in the 
I A group. These mutations, however, lead to severe cortical dysgenesis 
recognizable as lissencephaly (NDE1) or polymicrogyria (TBR2 and 
WDR62). 
Among these three genes only WDR62 mutations can be associated with an 
apparently normal cortex or simplifi ed gyration36,37. Mutations in other genes 
causing lissencephaly and polymicrogyria, such as LIS1 (Lissencephaly 1 
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MIM 601545), and TUBA1 (tubulin alpha-1-a MIM:611603), can also be 
associated with borderline microcephaly at birth and secondary stagnation 
of head growth38,39. This latter group is included in the Barkovich’s group 
II B, among the malformations due to generalized abnormal transmantle 
migration and will not be discussed in detail34. Group III D includes 
malformations with microcephaly secondary to abnormal postmigrational 
development, with head circumference at -2 SD below the mean at birth 
and progressing in short time to -4 or more SD This is where brain growth 
seems to slow after birth because of a rapidly progressing disease process 
and includes the X-linked CASK (calcium dependent-serine-protein-
kinase MIM:300749) mutations in females, the pontocerebellar hypoplasia 
mutations in transfer RNA splicing endonuclease subunit genes TSEN54 
(tRNA splicing endonuclease54 MIM:277470), TSEN2 (MIM:612389) and 
TSEN34 (MIM:612390), and many syndromes defi ned as developmental 
encephalopathies such as Rett syndrome caused by FOXG1 mutation 
(Forkhead box MIM:613454), Angelman syndrome (MIM:105830):, 
Pitt-Hopkins syndrome (MIM:610954) and Mowat-Wilson syndrome 
(MIM:235730) (Table 3).
For the scope of this thesis we will summarise and classify the primary 
microcephalies according to the radiological and pathological presentation 
and to the association with other congenital anomalies. 
Isolated Primary Microcephaly with normal or thin cortex 
on MRI (Table 1)
Table 1 summarises all the known primary microcephaly MCPH genes, 
cellular function, information when available from animal studies and 
human phenotype. MCPH is defi ned by the presence of normal or 
simplifi ed gyration and normal or thin cortex. MCPH refers to autosomal 
recessive loci identifi ed by linkage analysis in consanguineous pedigrees. 
A few of them will be discussed in detail as they are relevant to the 
present work.
The prevalence at birth of MCPH is dependent on population and 
ranges from 1 per million in the UK to 1 per 10000 in Pakistan refl ecting 
the increased incidence in a consanguineous population due to the AR 
inheritance pattern10. So far 9 loci have been identifi ed and the responsible 
genes discovered, these are MCPH1 (microcephalin MIM: 251200), 
WDR62, CDK5RAP2, CASK, ASPM, CENPJ (centromeric protein 7 
MIM: 608279), STIL (SCL/TAL-interrupting locus MIM: 18159), CEP135 
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(centrosomal protein MIM: 611423) and CEP152 (centrosomal protein 
MIM: 614852)22. It has also become clearer in recent years that MCPH 
is a genetic and phenotypically heterogenous disorder. The phenotype 
has particularly been expanded since the discovery of the MCPH2 
gene, WDR62, by whole exome sequencing40. Primary microcephaly is 
thought to arise from a decrease in neuro-proliferation and/or increase 
in apoptosis35. However, so far none of the known MCPH mutations are 
known to cause increased apoptosis, and all of the known MCPH genes 
do appear to encode proteins that have a role in the centrosome and thus 
probably infl uence neuroproliferation41. Prior to the discovery of WDR62, 
MCPH was associated with most mutations causing a truncated protein 
and cortical malformations were rare. The brain structure was thought to 
be preserved with only a simplifi ed gyral pattern being observed and the 
phenotype of the different MCPHs was thought to be indistinguishable from 
each other10. ASPM has been associated with epilepsy, simplifi ed gyral 
pattern, ventricular enlargement, partial corpus callosum agenesis and 
cerebellar hypoplasia43,44. Besides classic MCPH phenotype, in linkage-
unbiased whole exome sequencing studies, WDR62 mutations have been 
reported to have a broad clinical phenotype. Patients are reported with 
cortical malformations such as pachygyria, lissencephaly, schizencephaly 
and polymicrogyria36. The phenotype is not dependent on type of mutation, 
as chapter 4 explores. WDR62 and ASPM account for over 50% of all 
cases of MCPH45. The function of WDR62 is at present unknown but 
some investigators have showed that it is a centrosomal protein with an 
expression pattern similar to ASPM36, 37. 
MCPH1 is a protein that appears to have a dual role in centrosomal 
organisation and in DNA repair process, corresponding to the three breast 
cancer susceptibility protein C-terminal (BRCT) domains. The N-terminal 
BRCT domain has a role in cell cycle regulation and centrosome effects 
while the tandem BRCT2 and BRCT3 domains have a role in regulation of 
DNA damage46. Loss of MCPH1 leads to a premature entry into mitosis and 
premature chromosome condensation47. MCPH1 is required at multiple 
points in the DNA damage response including upstream of the ATM/ATR 
pathway and is required for recruitment of multiple involved proteins. 
MCPH1 is also indicated in regulation of transcription of DNA damage 
genes48. It is thought that the microcephaly in MCPH1 patients is caused 
by defective centrosomal function leading to decreased proliferation; 
however defective DNA repair can also cause microcephaly and this 
needs further exploration, as DNA repair defects also lead to microcephaly 
through different mechanisms (see chapter 3).
Introduction 17
Syndromic Microcephaly with normal or simplifi ed gyration 
and a normal or thin cortex (Table 2)
Some of the genes described in MCPH are also involved in Seckel 
Syndrome and/or microcephalic osteodysplastic primordial dwarfism 
(MOPD-I, II and III). Seckel and MOPD share microcephaly, intrauterine 
growth retardation, and distinctive facial features also called “bird 
headed dwarfism”. Seckel syndrome is a genetically and clinically 
heterogenous disorder. Known genetic causes include DNA repair 
genes such as ATR (ataxia-telangiectasia and RAD3 related MIM 
601215), RBBP8 (retinoblastoma binding protein-8 MIM 604124) and 
NIN (ninein MIM 614851) as well as the known microcephaly genes 
including CENPJ and CEP152 (Table 2). At present it is unclear as to 
why mutations in genes in some patients cause primary microcephaly 
and others cause Seckel syndrome. However centrosomal proteins 
are not the complete picture as many genes associated with Seckel 
syndrome are involved in the ATR-dependent DNA damage signalling 
pathway49. Interestingly, the Cenpj hypomorphic mouse, which 
shows a phenotypic similarity to Seckel syndrome with microcephaly, 
dwarfism and skeletal abnormalities, has increased apoptosis in the 
developing telencephalon and a reduced number of neurons which 
could contribute to the pathogenesis of microcephaly and intellectual 
disability50.
Centrosomal protein pericentrin (PCNT MIM:210720) mutations are 
associated with MOPD type II and Seckel syndrome, again showing an 
overlap with the MCPH. MOPD (I,II and III) is a disorder characterised 
by prenatal onset disproportionate short stature with mesomelic limb 
shortening and other skeletal distinctive features, primary microcephaly 
and distinctive facies and has a clinical overlap with MCPH and Seckel 
syndrome51. Lack of PCNT leads to disorganisation of the mitotic spindle 
and missegregation of the centrosome52. PCNT is shown to directly interact 
with MCPH1. A lack of either PCNT or MCPH1 leads to a defi ciency of cell 
cycle check point kinase, CHK1 at the centrosomes, which is essential in 
regulation of mitosis53. 
Effi cient DNA repair is essential for normal formation of the nervous 
system and microcephaly is a feature of several DNA repair disorders. 
However, its presence is an inconsistent feature, even within the spectrum 
of DNA repair syndromes caused by mutations in the same gene such 
as xeroderma pigmentosum (XP) syndrome and Cockayne Syndrome54. 
The underlying mechanism for congenital microcephaly is unclear in DNA 
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repair syndromes, although animal models hint to increased cell death 
being a possible mechanism55,56. A recent example of this in humans is 
discussed in depth in Chapter 3.1 of this thesis. Microcephaly, seizures 
and developmental delay syndrome (MCSZ, MIM 613402) is an autosomal 
recessive syndrome described by Shen et al caused by mutations in the 
polynucleotide kinase 3` phosphatise gene (PNKP)56. PNKP is involved 
in repair of both single strand breaks (SSB) and double-strand breaks 
(DSB)57,58 Interference studies of Pnkp in mouse neurons showed increased 
apoptosis in neuronal precursors and in differentiated neurons, suggesting 
apoptosis to play a role in the pathogenesis of the human disorder56. Other 
severe congenital disorders of DNA repair presenting with microcephaly, 
such as Cranio-oculo-facial-skeletal (COFS) syndrome are also listed in 
Table 2. COFS and PNKP-related syndromes are an object of study in 
Chapter 3. 
Examples of primary microcephaly syndromes associated 
with cerebral and extra cerebral abnormalities (Table 3)
Primary microcephaly can be associated with cerebral and extra 
cerebral abnormalities. We have summarised in Table 3 most 
syndromes consistently associated with head circumference below 
3SD at birth. This list includes the pontocerebellar hypoplasia`s (PCH) 
sub types 1-7 which present with hypoplasia of the cerebellum and the 
pons, progressive microcephaly, and variable cortical features, mostly 
simplifi ed gyration or generalised hypoplasia. PCH2 (MIM:277470), 
PCH4 (MIM:225753) and PCH5 (MIM: 610204) are associated with 
mutations in three tRNA subunit endonuclease subunits involved in 
tRNA splicing59.
 Wolcott-Rallison syndrome (WRS, MIM 226980) is an example of 
a multi-system syndrome which presents with neonatal diabetes, bony 
abnormalities and microcephaly with a simplifi ed gyral pattern and 
intractable seizures60. WRS is caused by EIF2AK3 mutations; this gene 
is involved in the regulation of protein synthesis during cellular stress 
conditions. The causative mechanism is increased apoptosis secondary 
to endoplasmic reticulum stress to which neurons and Islet of Langerhans 
cells seem to be particularly susceptible61,62. In this thesis patients with 
a phenotypic similarity to WRS, who do not bear the EIF2AK3 mutation as 
described leading to the hypothesis that this separate syndrome, also had 
increased susceptibility to apoptosis as a mechanism for the microcephaly 
and diabetes (chapter 2).
Introduction 19
Lissencephaly is defi ned as smooth and thickened cerebral cortex with 
a sparse cell zone caused by defective neuronal migration during midges-
tation. Barkovich’s classifi cation of cortical malformations includes a cat-
egory of microcephaly with lissencephaly34. The identifi ed genetic defects 
causing lissencephaly are LIS1, DCX (doublecortin MIM: 300121), RELN 
(reelin MIM: 600514), and TUBA1A. In this spectrum there are reports 
of association of microcephaly and lissencephaly known as “microlissen-
cephaly” (MLIS) but, in general, microcephaly is not a consistent feature 
of lissencephaly38. NDE1 mutations cause LIS4 or microlissencephaly 4. 
Extreme microcephaly is a consistent LIS4 feature with the head circum-
ference of affected individuals -10 SD below expected26. NDE1 interacts 
with LIS1 and DCX participating in the microtubule organising centre for 
nucleokinesis during neuronal migration, both proteins being encoded by 
genes involved in classic lissencephaly63. NDE1 protein has been shown 
to have a role in mitotic spindle formation and neuronal proliferation25 
showing similarities to the MCPH proteins. Interestingly WDR62 (MCPH2) 
mutations can be associated with a range of cortical malformations (such 
as pachygyria and polymicrogyria), or only a simplifi ed gyration27,36,37,64,65,68. 
This raises the question whether other (genetic) factors contribute to this 
phenotypic variability. 
In summary, what has previously been thought to be entirely separate 
conditions with distinct phenotype and genotypes have been shown 
in recent years to be more of a continuum with interaction and overlap 
between centrosomal proteins and DNA repair pathways. 
Practical Diagnostic approach to a child with microcephaly
A fl owchart may be of use to the clinician who is confronted with a micro-
cephalic child in order to accurately diagnose the type of microcephaly and 
to decide on relevant further investigations (fi gure 2). A thorough family, 
prenatal and birth history, and a complete examination are essential, and 
should include ophthalmological and hearing screening. 
If there are specifi c additional features suggesting a syndromic cause, 
ophthalmological assessment is especially vital. This can guide to specifi c, 
or even pathognomonic, signs of syndromal or infectious causes. In 48% of 
syndromes with microcephaly there is also ophthalmological involvement 
which can help diagnosis1. 
Neuroimaging, preferably MRI, in children with a head circumference 
of greater then -3SD below the mean has a diagnostic yield of between 
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58-80%67, 68. Also, there is a correlation between brain abnormalities and 
developmental abilities on the Bayley scales of development69.
 Although microcephaly is a genetically and clinically heterogenous disorder 
with phenotypical overlap, neuroimaging can guide us to targeted genetic 
testing and also has a prognostic value. Figure 2 summarises a diagnostic 
approach to the child with congenital microcephaly. 
Figure 2. Flow diagram summarising a clinical approach including investigations to a child 
with congenital microcephaly. 
Scope of the Thesis
Genetic studies of causes of congenital microcephaly have mostly 
been focused on disorders of proliferation. Even though in Barkovichs 
classifi cation it states that “increase in apoptosis of neuroprogenitors” can 
be a causative mechanism34, at the beginning of this study no forms of 
microcephaly in humans had been attributed to this mechanism. The aim 
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of this thesis is to describe new syndromes associated with microcephaly, 
novel genetic mutations and phenotypic variations, making use of state 
of the art genomic technologies. Additionally we provide some insights 
to novel mechanisms involving primary dysregulation of apoptosis of 
neuroprogenitors. 
In Chapter 2 (Brain Development and apoptosis) we applied traditional 
linkage analysis to data from SNP-arrays in order to identify the genetic 
cause of a new syndromic primary microcephaly. Two families are 
presented with a combination of microcephaly with simplifi ed gyration 
(MSG) and persistent neonatal insulin-dependent diabetes caused by 
a mutation in IER3IP1. Disease mechanism is attributable to increased 
apoptosis of neuronal progenitor cells and pancreatic beta islet cells, 
which was observed with studies on patient fi broblasts and post-mortem 
material.
In Chapter 3 (DNA repair and microcephaly) we approach the phenotypes 
and pathogenesis of microcephaly in DNA repair disorders. 
In Chapter 3.1 we applied whole genome sequencing (WGS) to 
identify the genetic mutation in a yet undefi ned syndromic microcephaly 
associated with progressive cerebellar atrophy, ataxia and severe 
peripheral polyneuropathy. We describe the phenotypic expansion 
of a known DNA repair syndrome caused by PNKP mutations in this 
family. We can explain the presentation by looking at predicted protein 
interactions and confi rm abnormal control of apoptosis as the proposed 
pathogenic mechanism.
In Chapter 3.2 severe cases of cerebro-oculo-facio-skeletal (COFS) 
syndrome caused by ERCC5 mutations who presented with a severe 
congenital microcephaly are described. Apoptosis is apparently implicated 
in the pathogenic mechanism of microcephaly in COFS with evidence from 
patient fi broblasts and mouse studies. We applied functional studies in 
human material to support our hypothesis.
In Chapter 4 (Microcephaly and cortical malformations), we tested 
the hypothesis that the phenotypic spectrum of cortical malformation 
in microcephaly can result from the contribution of multiple factors. 
Individuals with WDR62 mutations and variable phenotypic abnormalities 
are described. The observation of a mutation in TBCD, the gene for tubulin 
cofactor D, in the most severely affected individual leads to a proposal of 
polygenic inheritance as the hypothesis for explaining the wide phenotypic 
variation in WDR62 patients. 
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Brain development and apoptosis
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inappropriate apoptosis of neural progenitors
Cathryn J. Poulton, Rachel Schot, Sima Kheradmand 
Kia1, Marta Jones3, Frans W. Verheijen, Hanka Venselaar, 
Marie-Claire Y. de Wit , Esther de Graaff , 
Aida M. Bertoli-Avella, Grazia M.S. Mancini
Am J Hum Genet. 2011 Aug 12;89(2):265-76

Brain development and apoptosis 43
Abstract 
We describe a syndrome of primary microcephaly with simplifi ed gyral 
pattern in combination with severe infantile epileptic encephalopathy and 
early onset permanent diabetes in two unrelated consanguineous families 
with at least 3 affected children. Linkage analysis revealed a region on 
chromosome 18 with a signifi cant LOD score of 4.3. In this area, two 
homozygous non-conserved missense mutations in Immediate Early 
Response 3 Interacting Protein 1 (IER3IP1), were found in patients from 
both families. IER3IP1 is highly expressed in fetal brain cortex and fetal 
pancreas and is thought to be involved in ER stress response. We reported 
one of these families previously in a paper on Wolcott-Rallison Syndrome 
(WRS). WRS is characterized by increased apoptotic cell death as part 
of an uncontrolled unfolded protein response (UPR). Increased apoptosis 
has been shown to be a cause of microcephaly in animal models. Autopsy 
specimen from one patient showed increased apoptosis in the cerebral 
cortex and pancreas beta-cells, implicating premature cell death as the 
pathogenetic mechanism. Both patient fi broblasts and control fi broblasts 
treated with siRNA specifi c for IER3IP1, showed an increased susceptibility 
to apoptotic cell death under stress conditions compared controls. This 
directly implicates IER3IP1 in regulation of cell survival. Identifi cation of 
IER3IP1 mutations sheds light on the mechanisms of brain development 
and on the pathogenesis of infantile epilepsy and early onset permanent 
diabetes.
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Introduction
Microcephaly is defi ned as small brain size detected by a head circumference 
more than 2.5 SD below the mean for age and sex. Microcephaly can 
be either primary i.e. congenital and present at birth, or progressive, 
i.e. caused by decrease of head circumference growth rate, which was 
normal until birth. The incidence of primary microcephaly ranges from 
1/10.000 (consanguineous population) to 1/30.000 (non-consanguineous 
population)1. Primary microcephaly is considered to be caused by a brain 
developmental defect and at present the most widely accepted classifi cation 
of primary microcephaly is Barkovich’s et al. classifi cation which is 
based on brain MRI imaging and genetic knowledge2. The classifi cation 
includes microcephaly with a normal or a simplifi ed cortex (MSG, MIM 
603802), with a thickened cortex (microlissencephaly, presumed to result 
form a neuronal migration disorder), or with polymicrogyria (presumed 
to be caused by a defect of cortical organization) and other structural 
malformations. MSG is presumed to derive from abnormal neuronal and 
glial proliferation or apoptosis1. Mutations in at least seven genes (ASPM 
(MIM, 605481), MCPH1 (MIM,607117), CDK5RAP2 (MIM,608201), 
CEP152 (MIM, 613529), CENPJ (MIM 609279), WRD62 (MIM,613583) 
and STIL (MIM,181590))3 have been found that are causative for congenital 
primary microcephaly with normal or simplifi ed gyration which is broadly 
indicated as “higher functioning”, isolated microcephaly. These patients 
have near normal motor development with speech delay and moderately 
compromised cognition. Microcephaly with simplifi ed gyral pattern only, 
in a recent review represented the largest group of patients with primary 
microcephaly and almost all of these had near normal function with only 
mildly delayed mile stones and none had epilepsy5. 
In contrast, primary microcephaly also occurs in syndromes with additional 
features. In such cases, patients have a poorer neurological function, with 
severe cognitive and motor impairment and epilepsy as common symptoms. 
For this group of patients mutations in at least 4 genes (SLC25A19 (MIM 
606521)2, ATR (MIM 609215)3, ARFGEF2 (MIM 605371)4, RAB3GAP1 
(MIM 602536)4) have been identifi ed. 
Darvish et al recently reviewed genetic causes of microcephaly in 112 
Iranian families and came to the conclusion that the genetic cause is even 
more heterogeneous than previously thought6.
A common function of many known microcephaly genes (both isolated 
and with additional features) include a role in microtubule and centrosomal 
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organisation, regulating mitosis, which is postulated to occur via a disruption 
in the balance of symmetrical and asymmetrical division of neural progenitors 
in the proliferative layer of the developing cortex i.e. the ventricular and sub-
ventricular zone. This is dependent on correct centrosome and microtubule 
orientation to achieve the correct cleavage plane7.
 Despite this common theme, studies in animal models have shown that 
abnormal control of apoptosis can also be a pathogenic mechanism, 
therefore it has been proposed as a cause of human MSG but has thus far 
not been demonstrated in patients2. Apoptosis is an important regulatory 
mechanism of brain development specifi cally with the size of the forebrain8. 
Apoptosis is under complex control which results in activation of the 
caspase cascade and ultimately cell death. 
The assumption that regulation of apoptosis is necessary for normal brain 
development has been demonstrated in Mos+/- mice haploinsuffi cient for 
Magoh, the exon junction complex component, which controls brain size 
by regulating neural stem cell division. Mutant mice show a microcephaly 
both due to an increase in neuronal apoptosis and a depletion of the 
intermediate neuron progenitor population9. Additionally, mice defi cient in 
the RhoGTPase Rac1 produce a phenotype similar to primary microcephaly 
and also demonstrate an increase in apoptosis in the forebrain10.
In contrast a reduction of apoptosis leads to increased brain size in caspase 
9 knockout mice11. This further supports the hypothesis that a specifi c level 
of apoptosis is needed for normal brain development. 
In some human disorders, deletion or duplications at the same locus can 
alternatively cause either micro- or macrocephaly demonstrating a dosage 
effect and suggesting a primary regulation of brain size, hence of neural 
proliferation at that same locus12. 
In some cases apoptosis is a response to stress conditions, for example if 
an excess of unfolded proteins accumulate in the ER (ER stress). In such 
cases a cascade of events, collectively called unfolded protein response 
(UPR) provide suppression of protein translation. If this UPR mechanism 
fails, apoptotic cascades are triggered leading to cell death13.
Infantile onset permanent diabetes (PND, permanent neonatal diabetes, 
MIM 606176) has an incidence of approximately 1/260 00014. Unlike 
juvenile and adult onset diabetes it is not found to have an autoimmune 
cause. Instead the main mechanism is inappropriate apoptosis of 
Langerhans beta-islet cells, which are unable to cope with ER stress. This 
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has been described in Wolcott-Rallison Syndrome (WRS, MIM 226980), 
the most common cause of permanent neonatal diabetes in patients 
with consanguineous parents, which is caused by a mutation in the 
eukaryotic translation initiation factor 2-alpha kinase 3 gene, EIF2AK315. 
Patients exhibit a combination of PND associated with multiple epiphyseal 
dysplasia and variable additional clinical features, including psychomotor 
retardation, hepatic dysfunction and MSG16.
We have ascertained three patients from two consanguineous families with 
a striking overlapping phenotype. The affected children presented at an early 
age with the combination of MSG on MRI, infantile epileptic encephalopathy 
and infantile diabetes, resembling WRS and EIF2AK3 mutations had been 
excluded. We have previously described one of these patients as representing 
a phenocopy of WRS, with unknown cause16. We then performed linkage 
analysis and identifi ed overlapping areas of homozygosity by genomic SNP 
array analysis of the index patients. We hypothesized that these patients are 
suffering from a distinct genetic, presumably autosomal recessive syndrome 
and the results in this paper confi rm this hypothesis. 
Material and Methods
Pati ent material and RBI approval
All the family members and patient caretakers provided written informed 
consent for participation in the study and the genetic analysis was approved 
by the Erasmus Medical Centre research ethics committee.
Pathology study
A complete autopsy was performed in the male sibling of patient 2 (index 
patient 3, individual II:3 in fi gure 1B) shortly after his death at 26 months by 
one of the authors (Dr M. Jones) The material was fi xed in 10% formalin, 
and samples were analyzed on 5-μm thick hematoxylin and eosin-stained 
sections of paraffi n-embedded tissue. Immunohistochemistry for insulin 
was used in the pancreatic histological sections.
Brain was fi xed in 10% buffered-formalin and sectioned. Samples from 
frontal, parietal, temporal and occipital lobes, deep nuclei as well as 
cerebellum, brain stem and spinal cord were submitted for histological 
evaluation. This was performed on 5-μm thick hematoxylin and eosin-
stained sections of paraffi n-embedded brain tissue. Myelin stain (Luxol-
fast-blue) was also used. 
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SNP array, homozygosity mapping and linkage analysis
DNA from the index patients, the parents and unaffected siblings were hybridized 
to the arrays according to the Affymetrix standard protocol for the GeneChip 
Mapping 250K NspI array. Genotype data analysis was performed in Affymetrix 
GeneChip Genotyping analysis software (GTYPE) using the BRLMM algorithm. 
The obtained .CEL and .CHP fi les were used for homozygosity mapping in 
CNAG v3.017,18 and linkage analysis using Allegro in easyLINKAGE v2.119.
Sequencing analysis
Amplifi cation reactions were performed in a total volume of 20 μl, containing 
1x PCR buffer with Mg (Roche), 200 μM of each dNTP, 1 μM forward 
primer, 1 μM reverse primer, 0.1 units Fast Start Taq DNA polymerase 
(Roche) and 25 ng genomic DNA. PCR conditions: 5’ 960C, 10 cycles of 
30’’ 960C, 30’’ 680C (-10C/cycle), 60’’ 720C, followed by 25 cycles of 30’’ 
960C, 30’’ 580C, 60’’ 720C and a fi nal extension for 5’ 720C.
PCR reactions were purifi ed with ExoSAP-IT (USB). Direct sequencing of 
both strands was performed using Big Dye Terminator chemistry ver. 3.1 
(Applied Biosystems). DNA fragment analysis was performed using capillary 
electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems) and 
the software package Seqscape (Applied Biosystems, version 2.1). 
Microsatelite Markers Analysis
Amplifi cation reactions were performed in a total volume of 20 μl, containing 
1x PCR buffer with Mg (Roche), 200 μM of each dNTP, 1 μM forward 
primer, 1 μM reverse primer, 0.1 units Fast Start Taq DNA polymerase 
(Roche) and 25 ng genomic DNA. PCR conditions: 5’ 960C, 35 cycles of 
30’’ 960C, 30’’ 580C, 60’’ 720C and a fi nal extension for 5’ 720C.
PCR products were diluted and pooled in panels and loaded on an ABI 
3130 genetic analyser, with size standard LIZ 500 (Applied Biosystems) 
in formamide. Data was analyzed with Gene Mapper Version 2.1 software 
(Applied Biosystems).
Cell Culture and apoptosis
Fibroblast culture, RNA isolati on cDNA synthesis
Fibroblasts were obtained from the certifi ed Cell Repository of the department 
of Clinical Genetics, ErasmusMC, were routinely tested for mycoplasma and 
were cultured in 175 cm2 culture fl asks in Dulbecco’s modifi ed Eagle medium 
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(DMEM, Lonza Biowhittaker) until 80% confl uence. Total RNA was extracted 
with Trizol reagent (GIBCO BRL Life Technologies,) and purifi ed with Qiagen 
RNeasy mini columns (Qiagen,) according to manufacturers’ protocols.
Reverse transcriptase was performed on 1 μg RNA in a total volume of 
20 μl using iScript cDNA Synthesis Kit (BioRad) according to manufac-
turer’s instructions. 
Apoptosis Studies
Susceptibility to apoptosis studies were performed using patient cultured 
skin fi broblasts from the index patient of family 1, fi broblasts from a patient 
with confi rmed Wolcott-Rallison syndrome bearing an EIF2AK3 mutation15 
and 5 healthy control cells lines. Susceptibility to apoptosis of cultured 
skin fi broblasts was measured by fl uorescent staining of active caspases 
using the FlicaTM (Fluorescent-Labeled Inhibitor of Caspases) apoptosis 
multi-caspase detection kit (Immunochemistry Technologies, LLC), which 
makes use of an inhibitor sequence of active caspases, according to the 
manufacturer instructions. Fluorescent cells were scored before and after 
stress induction by 24 hours serum deprivation and then a further 24 
hours exposure to 5 mM dithiothreitol (DTT) by two blinded investigators 
as percentage of apoptotic fi broblasts. The experiment was repeated three 
times and each time performed in triplicate. Necrosis vs apoptosis was 
tested by vital staining exclusion with propidium iodide. 
Silencing experiments/RNA interference 
Pre-designed siRNA pools targeting human IER3IP1 (L-018948-01) (MIM 
609382) and non-target control pools (D-001810-10-20) were purchased 
from Dharmacon and used to knock down IER3IP1 in fi broblasts. siRNA 
was delivered to the fi broblasts via silentFECT Lipid Reagent (BioRad). 
Silencing was confi rmed at 24, 48 and 72 hours by RT-qPCR (primers: 
supplementary Table S2). Apoptosis was induced after 24 hours of serum 
deprivation, followed by addition of 1.25mM DTT for 24 hours; apoptosis 
was detected and percentages calculated using the FlicaTM apoptosis 
detection kit as above.
Quanti tati ve PCR (qPCR)
RT-qPCR was carried out using a KAPA SYBRH FAST qPCR Kit (Kapa 
Biosystems) in the CFX96 Real-Time system (BioRad). Thermal cycling 
conditions were as follows: denaturing step (95˚C for 3 minutes), followed 
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by 35 cycles of denaturing (95˚C for 5”), annealing and extension (60˚C 
for 30”). Fluorescence detection and data analysis were performed by 
BioRad CFX Manager 2.0. Experiments were performed in triplicate using 
as the reference UBE2D2 (Entrez GeneID 7322 [MIM 602962]) for gene 
expression normalization20.
Inducti on by TNF-alpha
Fibroblasts were cultured as above to 80% confl uency. In order to study 
induction of IER3 (MIM 602996) and IER3IP1 expression by TNF-alpha 
the cultures were exposed to two different conditions, 1st: standard culture 
medium (no induction with TNF alpha); 2nd: induction with 10ng/ml TNF alpha 
for 3 hours. After induction RNA was isolated with the Trizol LS protocol and 
RT-qPCR was performed for IER3 and IER3IP1 (primers in table S2).
Results
Pati ent descripti on
Family 1 
The index patient 1 (Individual II:1 in Figure 1A) was a male infant born to 
consanguineous parents (fi fth degree related, second cousins) of Moroccan 
origin (Figure 1A top panel). They also have two healthy daughters and 
a healthy son. The patient was born after a normal pregnancy and at birth 
his head circumference measured 2.5SD below the mean. At 2 months of 
age he presented with microcephaly greater than 3SD below the mean, 
developmental delay, hypotonia, epilepsy, obesity, presumed hypogonadism 
and infantile diabetes. At 2 months of age the seizures were a combination 
of focal seizures with secondary generalisation and generalised seizures. 
Electroencephalographs (EEG) showed high voltage asymmetric multifocal 
activity with abnormal background progressing into burst suppression on 
sleep EEG at 4 months and hypsarrythmia at 7 months. The MRI showed 
a simplifi ed gyral pattern of the cerebral cortex and delayed myelination, no 
overt cerebellar abnormality (Figure 2A-C). Additional metabolic and infection 
screening, including a muscle biopsy, was negative. ARX sequencing was 
normal. The diabetes and epilepsy were diffi cult to control despite treatment 
with clonazepam, vigabatrin and sodium valproate. Patient 1 died at the age 
of 18 months of a lower respiratory tract infection complicated by therapy-
resistant epilepsy and diabetes. A post-mortem exam was declined by the 
family. His clinical history has been reported by de Wit et al16.
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Figure 1. Family pedigrees and linkage data (A,B) Simplifi ed genealogical trees of two 
unrelated families with MSG, epilepsy and PND. Filled symbols represent affected patients. 
A double line represents consanguinity. An asterix represents subjects analysed by SNP 
arrays and included in the linkage analysis. The results of microsatellite markers analysis 
confi rming homozygosity are also shown. The shaded areas are the alleles containing the 
mutation and the box represents the area.
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Family 2 
Index patient 2 (Individual II:1 in Figure 1B) was the fourth affected child 
(there were also 2 similarly affected sons and 1 affected daughter) from 
a presumed consanguineous family in Argentina (Figure 1A, lower panel). 
He was born at term gestation after a normal pregnancy. Infantile diabetes 
and microcephaly, with a brain size greater then 3SD below the mean, 
were noted at birth. MRI performed at 2 months showed microcephaly 
with a simplifi ed gyral pattern (Figure 2). The seizures were generalised 
tonic-clonic and myoclonic in type. One EEG was performed at 2 years 
of age, which showed hypsarrythmia. After multiple hospital admissions 
with seizures and poor diabetic control, patient 2 died at 27 months from 
a lower respiratory tract infection complicated by epilepsy and diabetes. In 
the family three more siblings died of a similar disorder (reported as West 
syndrome and infantile diabetes) but medical records are not available.
Figure 2. Patient brain MRIs (A-C), MRIs from patient 1 performed at 1 year of age. (2A) 
T1-weighted image showing a simplifi ed gyral pattern and increased intra-cranial space 
with near-normal ventricular size. (2B-C) T2 weighted coronal and axial view showing 
equal involvement of parietal lobes, normal cerebellum and basal ganglia with delayed 
myelination. (2D-F) Low-resolution MRIs from patient 2 at approximately 7 months of age. 
(2D) Sagittal T1 weighted view showing a thin but present corpus callosum and normal 
brain stem, (2E) T1-weighted coronal view through the hippocampus showing simplifi ed 
gyration and hippocampal hypoplasia and (2F) T2- weighted view, demonstrating the 
simplifi ed gyral pattern and normal ventricular size.
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Pathology fi ndings
Post mortem macroscopic examination (performed after his death at 26 
months) of one similarly affected brother of patient 2 from the Argentinian family 
(index patient 3, Individual II:3 in fi gure 1B), confi rmed extreme microcephaly 
(weight 175g) compared to an age matched control (970g) and simplifi ed 
gyral pattern throughout the cortex with the temporal tips and interhemisperic 
parietal lobes showing extreme simplifi cation (Figure 3A-D). The cerebellum 
while relatively large compared to the cortex was also small (weight 59g, age 
 
Figure 3. Brain macroscopy and histopathology. (3A-B) Macroscopic view in real proportions 
of normal age-matched brain (upper specimen) compared with index patient 3 (individual 
II:3 in Figure 1B) post-mortem brain (lower specimen); note the extreme microcephaly and 
simplifi ed gyration looking almost lissencephalic in its medial surface. (3C-D) macroscopic 
photographs of patient 3 brain, showing shallow and insuffi cient in number sulci over the 
whole brain surface, but more apparent in the temporal and parietal lobes. Note photos 
3C and D are not in scale with 3A and B. (3E-J) Histopathology. (3E), Histopathology of 
normal cerebral frontal cortex (Age- matched to patient 3), (3F) patient 3 histopathology of 
the cerebral cortex showing numerous apoptotic neurons (arrows) an some apoptotic glial 
cells (H&E x 20). (3G) Cerebellar folia: Purkinje neurons are apoptotic (arrows) and internal 
granule cell layer is diminished (H&E x 20) (3H) Nearly all neurons and the inferior olivary 
nuclei are apoptotic. (3J) Patient 3 pancreas stained for insulin showing depletion of insulin 
producing islet cells in comparison to a normal pancreas (3I). 
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matched control 125g). Microscopy revealed reduced number of neurons in 
the brain cortex, mainly of layers 1 and 4, hypomyelination and remarkable 
apoptosis. Many picnotic dead cells were also observed in the inferior olivary 
nucleus and in the cerebellum while the pancreas showed few and small islets 
with few insulin positive beta cells (Figure 3E-G). 
Molecular analysis
The 250K SNP array data from the index patients (probands), unaffected sibs 
and parents were analysed for loss of heterozygosity (LOH) regions using 
CNAG and the pedigrees were subsequently used for easyLINKAGE19. 
In both families multiple areas of apparent LOH larger than 1 Mb were observed 
in the probands, suggesting homozygosity and compatible with the reported 
consanguinity. We observed one LOH region on chromosome 18 overlapping 
between patients from the two families. We then performed a linkage analysis 
on the SNP array data and found a signifi cant LOD score of 4.3 linked to the 
same region on chromosome 18q, spanning a 10Mb region and containing 
43 genes (NCBI built 36.3). The region was confi rmed as homozygous in 
the affected and heterozygous in the unaffected siblings by microsatellite 
markers (Figure 1A and supplementary Figure S1).
The genes in the linkage area were prioritised for sequencing using 
available expression data from GEO profi le. In total 12 genes were 
found to be expressed both in the brain and pancreas and these were all 
sequenced (Table S1). In both affected individuals from the two pedigrees 
a homozygous variation in the Immediate Early Response-3 Interacting 
Protein-1 (IER3IP1) was found In index patient 1 (Individual II:1 in Figure 
1A) a homozygous missense change was found in exon 1, c.62T>G, 
(NM_016097.3) causing a change in amino acid at position 21 from Valine 
to Glycine (p.Val21Gly). In index patient 2 (Individual II:1 in fi gure 1B) 
a homozygous missense change was found in exon 3, c.233T>C. This 
causes a change in amino acid at position 78 from Leucine to Proline 
(p.Leu78Pro) (Figure 4A). The parents in both families were confi rmed 
heterozygotes for the changes, while the non-affected sibs were confi rmed 
either heterozygotes or had no changes. Unfortunately, no DNA of index 
patient 3 was available. Neither of these changes was annotated in dbSNP 
132 or the 1000 genome database, or was found in 300 ethnically matched 
control chromosomes, indicating in each case an allele frequency lower 
than 0.3%. 
No change predicted to be pathogenic was observed in any of the other 
genes in the linkage area in the affected subjects. 
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In silico IER3IP1 functi on predicti on and mutati on eff ect 
IER3IP1 encodes a small polypeptide protein of about 10 kDa21. Protein 
localisation studies of IER3IP1 and the yeast homologue Yos1p localise the 
protein to the ER and Golgi and suggest its involvement in control of COP-II 
vesicle budding21,22. The protein sequence predicts one N-terminal hydrophobic 
domain possibly including a signal peptide sequence23, a hydrophilic glycine-
rich domain containing (G-patch), putatively interacting with RNA, and 
a C-terminal second hydrophobic trans-membrane domain (Figure 4A). Signal 
P 3.0 server23 predicts a hydrophobic domain, including a signal peptide which 
is required for targeting the peptide to the endoplasmic reticulum (ER). The 
p.Val21Gly change is located in this fi rst domain and introduces a new glycine 
just before the G-patch. Signal P 3.0 suggests that this mutation is very close 
to a putative peptide cleavage site, possibly interfering with the cleavage of 
the signal sequence23. Preliminary data show that IER3IP1 is undetectable in 
fi broblasts from patient 1 (supplementary Figure S5). The p.Leu78Pro change 
is located in the second trans-membrane domain. Using Project HOPE and 
tools for predictions of amino acid changes on protein structure, both mutations 
are predicted to cause a change in protein structure and are predicted to 
be within a hydrophobic/trans-membrane domain24,25. The p.Leu78Pro is 
predicted to be within an alpha helix and is predicted to have severe effects on 
the structure of the protein (supplementary Figure S4).24,25 In silico analysis of 
the p.Val21Gly by the Grantham Matrix Score26, Polyphen-227, SIFT28, SNAP29 
and Pmut30 programmes predicted in a pathogenic/non-neutral effect, (see 
supplementary Table S3). The p.Leu78Pro was predicted to be pathogenic/
non-neutral by the Grantham Matrix Score26, Polyphen-227, SNAP29 and 
Pmut30 programmes (see supplementary Table S3). Both mutations are in 
a highly conserved area among vertebrates (Figure 4A). Although very little 
has been published about IER3IP1, search in several in silico expression 
databases (GEO profi le, GenePaint, Allen Brain Altlas, MGI, EMBL-EBI) 
brought additional information about its putative function. The mouse homolog 
Ier3ip1 shows a high level of expression during early gestation (E9.5 and 
E11.5, compared to E13.5) which corresponds to the period of proliferation of 
neural progenitors. In the developing mouse at E14.5 there is high expression 
of Ier3ip1 in the developing mouse cortex in the ventricular/sub-ventricular 
zone at the site of neurogenesis31 (Figure 4B).
Expression in embryonic pancreas peaks at E12.5 and lowers at E13.5 
and E14.5 (GEOprofi le, GenePaint). There also appears to be expression 
in the lungs and the kidneys. The IER3IP1 mRNA is putatively translated 
into the endoplasmic reticulum, suggesting that it functions indeed as 
a membrane bound protein (EMBL-EBI database). In adult mouse brain its
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Figure 4. IER3IP1 sequence and expression in developing brain. (4A) Schematic 
representation of the human IER3IP1 protein showing the sequence, the predicted protein 
domains and the location of the p.Val21Gly and the p.Leu78Pro mutations. Cross species 
conservation of IER3IP1 in the areas of the mutations is shown at the bottom of the 
diagram. Both the predicted amino acid changes are in a highly conserved area of the gene 
and in the hydrophobic/transmembrane domains and are depicted in red. (4B) Expression 
of Ier3ip1 at E14.5 days in the whole mouse embryo (left); zoomed in, in the right panel is 
the mouse brain, with arrows pointing to increased expression in the ventricular and sub-
ventricular zone at the site of neurogenesis24.
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expression is low and essentially limited to the cerebellum, hippocampal 
area, midbrain and thalamus, with low, albeit detectable expression in the 
cortex (Allen Brain atlas). There is also additional evidence that IER3IP1 
is down-regulated by miR-34a32. Once trans-activated by p53, this micro-
RNA is known to promote apoptosis32. This data suggest a putative function 
for IER3IP1 in protecting neural progenitors in the proliferative zone of the 
embryonic forebrain from apoptosis. 
Apoptosis tests in vitro
As a next step we tested the general tendency of cultured fi broblasts to 
undergo apoptosis by use of a test for active caspases after induction of 
stress by dithiothreitol33.
Fibroblasts in an individual with an IER3IP1 mutation showed an signifi cantly 
increased tendency to undergo apoptosis after treatment with DTT in 
comparison to control cells (p≤0.001, unpaired t-test, SPSS version 17.0) (Figure 
5A). The rate of apoptosis was similar to the cells of a patient with confi rmed 
Wolcott-Rallison syndrome16. However, considering the p.Val21Gly missense 
mutation could synthesize an abnormal protein, increased apoptosis could be 
the result of a putative ER stress induced by a less functional IER3IP1 protein 
accumulating in the ER and not be linked to a specifi c function of IER3IP1 
in protecting the cells from apoptosis. We therefore tested the susceptibility 
to stress induced by DTT after silencing of IER3IP1 in control fi broblasts by 
specifi c small interfering RNA. RT-q-PCR of the IER3IP1 transcript showed 
effi cient down-regulation, i.e. diminished predicted IER3IP1 synthesis (Figure 
5B, left panel) In cells where IER3IP1 had been knocked-down a signifi cant 
increase (p≤0.001, unpaired t-test, SPSS version 17.0) in apoptosis was 
observed after stress induced by 1.25mM DTT, when compared to the 
same cell line treated with control siRNA (Figure 5B, right panel). The DTT 
concentration in these experiments was lower because the siRNA treatment 
made cells more susceptible to apoptosis (also seen in control experiments). 
No difference in the level of apoptosis was observed in the absence of stress 
or when the cells were only exposed to serum deprivation (data not shown).
These results demonstrate that IER3IP1 is needed in vitro to protect cells 
from the consequences of stress induced by denaturing agents like DTT.
TNF-alpha experiments
In the gene annotation databases, the IER3IP1 protein is considered as 
a putative interactor of IER3, the Early Immediate Response-3 regulating 
acute stress response and cell death through the TNF-alpha pathway34, 
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but any evidence for the human protein is lacking. In control fi broblasts, 
we found that expression of IER3 mRNA was approximately 10 fold higher 
after induction with TNF-alpha in comparison to standard culture conditions 
(p<0.0001, unpaired t-test, SPSS version 17.0) (fi gure 5C). To test if IER3 
Figure 5. Susceptibility of cultured fi broblasts to apoptosis and TNF-alpha stimulation. 
(5A): Patient cells are more susceptible to apoptosis similar to cells from a known WRS 
patient, when treated with 5mM DTT in comparison to 5 control cell lines (p≤0.001, unpaired 
t-test, SPSS version 17.0). Values represent a mean of 3 experiments +/-SEM. (5B): 
IER3IP1 expression levels in control fi broblasts are approximately 10 fold decreased after 
addition of IER3IP1 siRNA in comparison to control siRNA (p≤0.001, unpaired t-test, SPSS 
version 17.0) (left panel). Control fi broblasts treated with IER3IP1 siRNA also demonstrate 
a signifi cantly increased susceptibility to apoptosis (p≤0.001, unpaired t-test, SPSS 
version 17.0) when treated with 1.25mM DTT in comparison to control fi broblasts (right 
panel). Values represent a mean of 3 experiments +/-SEM. (5C) IER3 mRNA levels are 
approximately 10 fold increased in patient and control cells after addition of TNF-alpha (left 
panel) (unpaired t-test SPSS version 17.0,P<0.0001). IER3IP1 levels are approximately 
1.5 fold increased in patient and control fi broblast cell lines after addition of TNF-alpha 
(p<0.001, unpaired t-test SPSS version 17.0)(right panel). Stars represent a signifi cant 
p<0.01 difference. 
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and IER3IP1 are similarly regulated we looked at the expression of IER3IP1 
after the addition of TNF-alpha. There was an approximate 1.5 fold increase 
in expression of IER3IP1 mRNA after induction with TNF-alpha both in 
patient and control fi broblasts (p<0.001, unpaired t-test, SPSS version 17.0) 
suggesting that IER3IP1 is under similar control as IER3 (Figure 5C). 
Discussion 
We have described a syndrome consisting of MSG, PND, severe apoptotic 
brain and infantile epileptic encephalopathy in patients from two separate 
families, associated with mutations in the IER3IP1. 
Collectively, the linkage and IER3IP1 sequence data together with the 
expression pattern during brain development and its involvement in 
regulation of apoptosis in vitro indicate that the mutations observed in our 
patients are causally related to their disease. 
The congenital microcephaly and insulin dependent diabetes can be 
explained by the presence of abnormal levels of neuronal apoptosis in 
brain and pancreas specimen from the sibling of patient 2. In this brain 
there is additional evidence for insuffi cient myelination, which suggests 
either that early common progenitors of both neural and glia lineage 
are depleted or that maturation of the oligodendrocyte progenitors is 
blocked. Consistent with the hypothesis of progenitor depletion and 
block in maturation, the pattern of Ier3ip1 in mouse brain at embryonic 
day 14.5 shows selective expression at the proliferative ventricular and 
sub-ventricular zone, where the common neuro-glial progenitors are 
located before differentiation in to separate lineages. Although naturally 
occurring cell death represents a fi nal pathogenic mechanism of many 
disorders, apoptosis is an essential and impressive feature of cortical 
brain development. During neurogenesis, about 70% of progenitor 
cells in the ventricular and sub-ventricular zone undergo apoptosis, 
this number being similar to that of post-mitotic cells, leading to the 
suggestion that apoptosis controls stem cell population35. Abnormal 
increase of apoptosis in the IER3IP1 patients could either be the result of 
insuffi cient regulation of mitosis and differentiation of neural progenitors 
or insuffi cient protection from pro-apoptotic stimuli. Distinction between 
these two mechanisms might be particularly important for the identifi cation 
of pro-apoptotic stimuli extrinsic to the cell metabolism, like oxidative 
stress, which might be preventable36. Fibroblasts from an individual 
with an IER3IP1 mutation show increased rates of apoptotic cell death 
when exposed to DTT. Additionally, silencing of the IER3IP1 leads to 
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increase in apoptosis rate in control fi broblasts after DTT treatment. On 
the one hand these results link the effect of the mutation with the onset of 
apoptosis, on the other hand they suggest that IER3IP1 intervenes under 
“stress” stimuli. IER3IP1 is putatively involved in cell differentiation and 
cell death processes, under regulation of transcription factors TNF-alpha 
and Sp134. If IER3IP1 normally protects the cell from stimuli inducing 
apoptosis, the modest albeit signifi cant response to TNF-alpha places 
human IER3IP1 in the “death receptors” cascade37. IER3IP1 has also 
a reported role in ceramide apoptosis in neurons38.
IER3IP1 is a highly conserved protein that is found in humans, mice, 
zebrafi sh (Figure 4A) and yeast (homolog to Yos1p) and is highly expressed 
in the developing cortex and in the beta cells of the pancreas. IER3IP1 
putatively interacts with IER3 and, based on its sequence homology to 
the yeast protein Yos1p and preliminary experimental evidence, it is an 
endoplasmic reticulum protein containing at least one trans-membrane 
domain and mediating vesicular transport between Golgi and ER33. 
However, it also contains a G-patched domain present in RNA-associated 
proteins. 
IER3IP1 has a similarity in name to and may interact directly with IER3, 
although there is no available experimental evidence published to prove 
this. IER3 is a highly conserved protein consisting of 156 amino acids in 
humans and consists of a putative trans-membrane domain and a nuclear 
localisation site. IER3 is described as having both a pro and anti-apoptotic 
role39,40.
An elevated expression of IER3 in hepatocytes and pancreatic tumour 
cell lines triggers apoptosis in response to various apoptotic stimuli. 
IER3 has also been reported to be part of the DNA damage-induced and 
p53mediated apoptosis in rodent and human cells40.
Our experiments showing increased expression of IER3 and IER3IP1 
after induction with TNF-alpha could provide clues that IER3IP1 regulates 
apoptosis via interaction with IER3, either through cooperation or through 
interference with IER3 function.
We therefore conclude that IER3IP1 is an important gene,, involved 
in the development of microcephaly and diabetes via dysregulation of 
apoptosis.
The role of IER3IP1 in cortical development and pathogenesis of 
epilepsy and diabetes is obscure but it seems essential from the 
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early stages of development, such as the period of neural progenitor 
proliferation. It is unknown when the diabetes starts in the patients 
because there has been no way to test it prenatally, but the presence 
of microcephaly with simplifi ed gyration indicates a crucial role already 
during gestation. Severe infantile epileptic encephalopathy is very 
unusual in primary microcephaly and has only been reported in patients 
with WDR62 mutations41. In these patients, however, the structure of the 
cortex is deeply abnormal and shows both migration and organization 
defects, both high risk factors for epilepsy. The rare combination of 
primary microcephaly with severe infantile epilepsy has been observed 
in PNKP mutations42. In this disorder, seizures and microcephaly are 
not related to degenerative changes, but to probable defects in DNA 
repair mechanisms of nucleotide excision or single/double stranded 
breaks. Interestingly, mouse neuronal cells show increased apoptosis 
rates when PNKP is silenced by siRNA. 
Apoptosi s or programmed cell death is also end point of the unfolded 
protein response. WRS, which shows phenotypic similarity to our patients’ 
syndrome, is caused by a mutation in the EIF2AK3, which encodes 
a kinase in the ER membrane, one of four that phosphorylates EIF2a 
(also known as Perk in mice), having an important role in the unfolded 
protein response15. When a protein is misfolded, EIF2a is phosphorylated 
resulting in lower levels of translation initiation of the protein and eventually 
prevention from apoptosis. This is proven by the Perk knock out mice, 
which have an increased rate of apoptosis and destruction of beta cells 
causing a similar phenotype to WRS in humans43. It is interesting that both 
of the IER3IP1 mutations found are in the putative hydrophobic regions 
which therefore seem to be functionally very relevant. It is possible that the 
role of IER3IP1 in protecting from apoptosis is also played by regulating 
and/or preventing nascent protein (mis)folding in the ER membrane, at the 
lumen and thus preventing activation of the UPR response. This and other 
questions might be addressed by future protein studies on subcellular 
localization and on identifi cation of interacting partners. These studies will 
also be instrumental in the understanding of severe infantile epilepsy and 
infantile diabetes. 
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Supplementary data (5 fi gures and 3 tables)
Figure S1. Results of the whole genome scan from EasyLINKAGE.
Signifi cant peaks (>3) were found on chromosomes 13 and 18 (X axes). The 
highest was on chromosome 18 (4.3). However when these were analysed 
individually only the peak on chromosome 18 remained signifi cant. 
Figure S2. HOPE project prediction of IER3IP1 mutation (p.Val21Gly) effects on the protein.
We observed a mutation of a Valine into a Glycine at position 21. The fi gure 
below shows the schematic structures of the original (left) and the mutant 
(right) amino acid. The backbone, which is the same for each amino acid, is 
coloured red. The side chain, unique for each amino acid, is coloured black.
The residue is located in a region annotated in the Uniprot database as 
a transmembrane domain. The new mutant residue is smaller than 
the wild-type residue. This can disturb either the contacts with the other 
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transmembrane domains or with the lipid-membrane. The wild-type residue 
was more hydrophobic than the new mutant residue. This can affect the 
hydrophobic interactions within the core of the protein or with the membrane 
lipids. The mutation introduces a glycine at this position. Glycines are very 
fl exible and can disturb the required rigidity of the protein on this position. 
The wild-type and new mutant amino acids differ in size. The new mutant 
residue is smaller than the wild-type residue. The mutation will cause an empty 
space in the core of the protein (or protein-complex). The hydrophobicity of 
the wild-type and new mutant residue differs. The mutation will cause loss 
of hydrophobic interactions in the core of the protein (or protein-complex). 
Figure S3. HOPE project prediction of IER3IP1 mutation (p.Leu78Pro) effects on the protein. 
We found a mutation of a Leucine into a Proline at position 78. The fi gure 
below shows the schematic structures of the original (left) and the mutant 
(right) amino acid. The backbone, which is the same for each amino acid, is 
coloured red. The side chain, unique for each amino acid, is coloured black
Figure S4. Disruption of alpha-helix in p.Leu78Pro.
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The residue is located in a region annotated in the Uniprot database 
as a transmembrane domain. The new mutant residue is smaller than 
the wild-type residue. This can disturb either the contacts with the 
other transmembrane domains or with the lipid-membrane. The wild-
type residue is predicted (by the PHDacc DAS-server) to be located 
in an α-helix. Proline disrupts an α-helix when not located at one of 
the first two positions. In case of the mutation at hand, the helix will 
be disturbed and this can have severe effects on the structure of the 
protein. 
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Figure S5. Western blot of IER3IP1.
Western blot showing IER3IP1 is detectable in 2 control fi broblast 
homogenates (lane 2 and 3) using specifi c custom made polyclonal (rabbit 
anti human) antibodies raised against the whole polypeptide (SciLight 
Biotechnology Ltd.), but not in fi broblasts from index patient 1, ( individual 
II:1 in Figure 1A), (lane 1). 
On the SDS-polyacrylamide gel, the molecular weight marker of 10KDa 
indicates the level of the IER3IP1 protein band. Protein homogenate in 
each lane was obtained from about 7 x 106 cultured cells, equivalent of one 
T175 cm2 fl asks. The results were reproduced in two separate experiments. 
The last 3 lanes in the picture are empty.
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Table S1. List of sequenced genes in shared homozygous area.
Ensemble Gene id Descripti on
ENSG00000152240 HAUS augmin like complex subunit 1 
[Source:HGNC Symbol;Acc:25174]
ENSG00000197046 SIGLEC15 sialic acid binding Ig-like lecti n 15 
[Source:HGNC Symbol;Acc:27596]
ENSG00000152234 ATP5A1 ATP synthase, H+ transporti ng, mitochondrial F1 complex, 
alpha subunit 1, cardiac muscle [Source:HGNC Symbol;Acc:823]
ENSG00000167220 HDHD2 haloacid dehalogenase-like hydrolase domain containing 2 
[Source:HGNC Symbol;Acc:25364]
ENSG00000132872 SYT4 synaptotagmin IV 
[Source:HGNC Symbol;Acc:11512]
ENSG00000134049 IER3IP1 immediate early response 3 interacti ng protein 1 
[Source:HGNC Symbol;Acc:18550]
ENSG00000134049 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group) [Source:HGNC Symbol;Acc:10918]
ENSG0000015229 PSTPIP2 proline-serine-threonine phosphatase interacti ng protein 2 
[Source:HGNC Symbol;Acc:9581]
ENSG00000175387 SMAD2 SMAD family member 2 
[Source:HGNC Symbol;Acc:6768]
ENSG00000152217 SETBP1 SET binding protein 1 
[Source:HGNC Symbol;Acc:15573]
ENSG00000152242 C18orf25 chromosome 18 open reading frame 25 
[Source:HGNC Symbol;Acc:28172]
Table S2. Primers used for RT-q-PCR experiments (Figure 5).
Primer pair Forward Reverse
IER3IP1 
spanning exon 2-3
CAGGGAATTGGTGGATTTGG TGGCACTCTCATCACGGTTCT
IER3 
spanning exon 1-2
TCTTCACCTTCGACCCTCTC GGGTTCGGTTCCTCGACT
UBE2D2
spanning exons 5 
and 6 
GATCACAGTGGTCTCCAGCA CGAGCAATCTCAGGCACTAA
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Table S3. Summary of mutation prediction program output for the p.Val21Gly and 
p.Leu78Pro mutations in IER3IP1. 
p.val21Gly p.Leu780Pro
Polyphen2 HumVar Probably damaging (0.978) Probably damaging (0.956)
Polyphen2 HumDiv Possibly damaging (0.830) Possibly damaging (0.634)
Grantham Matrix Score 109 (pathological) 78 (pathological)
SIFT Aff ect protein functi on (score 0.0) Tolerated (score 0.16)
SNAP Non-Neutral Non-Neutral
pmut Pathological (0.99) Pathological (0.8668)
Mutati on taster Disease causing (0.99) Not available
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Abstract
We present a neurodegenerative disorder starting in early childhood of 
two brothers consisting of severe progressive polyneuropathy, severe 
progressive cerebellar atrophy, microcephaly, mild epilepsy and intellectual 
disability. The cause of this rare syndrome was found to be a homozygous 
mutation (c.1250_1266dup, resulting in a frameshift p.Thr424GlyfsX48) in 
PNKP, identifi ed by applying homozygosity mapping and whole genome 
sequencing. Mutations in PNKP have previously been associated with 
a syndrome of primary microcephaly and seizures (MCSZ syndrome, 
MIM 613402), but not with a neurodegenerative disorder. PNKP is a dual 
function enzyme with a key role in different pathways of DNA damage 
repair. DNA repair disorders can result in accelerated cell death, leading 
to underdevelopment and neurodegeneration. In skin fi broblasts from 
both affected individuals we show increased susceptibility to apoptosis 
under stress conditions and reduced PNKP expression. PNKP is known to 
interact with DNA repair proteins involved in the onset of polyneuropathy 
and cerebellar degeneration, therefore our fi ndings explain this novel 
phenotype.
Keywords: DNA repair, microcephaly, polyneuropathy, cerebellar atrophy, 
PNKP, MCSZ syndrome
 Chapter 376  
Introduction
From the fi rst identifi cation of the basis of mendelian disorders using whole 
exome sequencing (WES)1 and whole genome sequencing (WGS)2,3 these 
techniques have rapidly emerged as effective methods in fi nding disease-
causing mutations. In consanguineous pedigrees this can be combined with 
homozygosity mapping for rapid candidate gene fi ltering4. Two siblings from 
a Dutch isolated population presented to our clinic with a rare combination of 
features starting in early childhood consisting of ataxia caused by progres-
sive cerebellar atrophy, progressive debilitating polyneuropathy, microceph-
aly, severe intellectual disability (ID) and mild epilepsy. No ocular signs or in-
volvement of other organs were present. No known disorder was compatible 
with this phenotype (including known DNA repair disorders and hereditary 
neuropathies), extensive metabolic work-up was normal. The MRI patterns 
were not typical for known cerebellar ataxia with polyneuropathy syndromes, 
such as infantile neuroaxonal dystrophy or neuroacanthocytosis. 
Despite multiple expert opinions and laboratory studies we were unable to 
establish a defi nitive clinical diagnosis. We therefore pursued a genotype-
fi rst approach and chose a combination of homozygosity mapping and whole 
genome sequencing approach in order to minimize the chance of missing 
known and putative pathogenic mutation(s) in both coding regions and splice 
sites5. The same strategy has been successfully used to screen all known and 
identify new hereditary motor and sensory neuropathy (HMSN) genes2. To our 
surprise we identifi ed a homozygous mutation in PNKP (MIM:605610) in both 
affected siblings by WGS and confi rmed the disease locus with homozygosity 
mapping. Mutations in PNKP (polynucleotide kinase 3`-phosphatase) 
have been described in an autosomal recessive disorder characterized by 
microcephaly, seizures and developmental delay (MCSZ, one of the early 
infantile epileptic encephalopathies, EIEE10, MIM: 613402)6. The MCSZ 
patients are phenotypically very different to the patients described, who did 
not show any clinical progression, or any neurodegenerative symptoms. 
Additional studies in patient cells indicate a role of increased apoptosis in the 
pathogenesis of this novel degenerative phenotype. 
Clinical Reports
The parents of our patients are healthy and originate from an isolated 
community in the southwest of the Netherlands. Genealogical studies of 
the family pedigree showed a loop of consanguinity (Figure 1A). 
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Figure 1. A: Pedigree of the family showing common ancestor couple and the link to 
a possibly third affected family member. PNKP genotype is shown below individuals: *= 
1250_1266 dup, wt= “wild type” PNKP sequence, black boxes represent affected persons. 
B: Sanger sequencing results of PNKP in patient 2, the sequence present in duplo is 
shaded in pink and yellow.
Patient 1 was born at term with microcephaly (occipito-frontal 
circumference, OFC -3.25 SD), and weight and length at -1 SD. He had 
developmental delay, at 15 months he was able to take a few supported 
steps, and say ‘daddy’ and ‘mama’. At this age his OFC was -5.7 SD. At 
23 months he walked independently, with a broad based ataxic gait. He 
had brisk tendon refl exes. He presented with a series of febrile seizures at 
2.5 years, and experienced occasional seizures, mostly febrile, thereafter. 
His global development was compatible with 17 months at age 4.5 years 
(Bayley scale of development). The boy was hyperactive and always had 
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an extreme happy behaviour. The diagnosis Angelman syndrome was 
considered, but DNA testing was negative. At age 9 he was a restless 
boy with severe progressive microcephaly (-6 SD), short stature (-4 SD), 
ataxic gait, speaking 5 to 10 words. A brain MRI at age 16 showed severe 
cerebellar atrophy (Figure 2, A-C), while a CT made at the age of 10 months 
showed no atrophy of the cerebellum at all.
A slow deterioration of motor skills became evident, and he became 
wheelchair bound at age thirteen (see supplemental video). Motor function 
further deteriorated over the next few years, mostly as the consequence 
of progressive signs of the peripheral neuropathy, i.e. paresis of arms 
and legs accompanied by hypotonia, muscular atrophy, loss of the 
initially brisk tendon refl exes, and the development of contractures. 
A progressive severe motor and sensory demyelinating polyneuropathy 
with axonal degeneration was shown on EMG at age 11 and 16 (Table 
1). In contrast to the motor deterioration, cognitive functions and speech 
performance remained stable, while the epilepsy improved. He retained 
a happy demeanour, but had temper tantrums in adolescence. He died of 
pneumonia at 25 years. 
Patient 2, the younger brother of patient 1, was born at term with birth 
weight at +0.5 SD, length at -0.25 SD, and OFC at -1.5 SD. At 3 months 
microcephaly (-3.5 SD) and developmental delay were noted. His fi rst 
seizure occurred at 12 months. He walked independently at 18 months and 
showed also hyperactive and happy behaviour. At fi ve years he developed 
strabismus and papilloedema consistent with raised intracranial pressure 
and a ventriculo-peritoneal shunt was placed. He slowly lost his ability to 
walk, and started using a wheel chair from age 7 (see supplemental video). 
At age 14 his OFC was -4.75 SD, and he was a hyperactive boy who could 
speak about 10 words. EMG at age 10 and 16 showed demyelinating 
polyneuropathy (Table 1). Brain MRI at age 15 months showed enlarged 
lateral ventricles and thin corpus callosum (Figure 2, D-F), and at age 9 and 
18 years, after placement of the VP drain, showed a severe progressive 
cerebellar atrophy, and mild cerebral atrophy (Figure 2, G-L). Seizures 
occurred 3-4 times a year while on carbamazepine therapy, but later on 
the frequency decreased. No eye problems, skin rash or susceptibility to 
infection were ever observed in the brothers. 
A second-degree cousin of the father (Figure 1A) had a similarly affected 
son who died around 30 years of age of a progressive neurological disease. 
No medical records are available. He had a small head, seizures and had 
lost the ability to walk. 
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Metabolic investigations including lactate, vitamin A and E, very long chain 
fatty acids, sialotransferrin isoforms, erythrocyte and leukocyte morphology, 
lysosomal enzymes, urine organic acids, mucopolysaccharides and 
amino acids, and CSF neurotransmitters were normal in both brothers. 
Transcription-coupled nucleotide excision repair after UV treatment 
(diagnostic test for Cockayne syndrome) and inhibition of DNA synthesis 
after X-ray irradiation (diagnostic test for ataxia-telangiectasia) were 
normal in patient fi broblasts (see below). 
A video of patient 1 and 2 at different ages showing ataxia and progressive 
deterioration is included in the supplemental data (with consent of the family).
Figure 2. MRI imaging of patient 1 (A-C) and patient 2 (D-L). First two columns show 
transversal T2-weighed images, the third column shows sagittal T1-weighed images. A-C: 
patient 1 age 16 years, microcephaly, generalized atrophy, enlarged ventricles, and severe 
cerebellar atrophy. D-F: patient 2 age 15 months, mild generalized atrophy, enlarged 
lateral ventricles and thin corpus callosum. G-I: age 9 years, and J-L: age 18 years, show 
decrease of lateral ventricle sizes after placement of VP-drain, severe and progressive 
cerebellar atrophy. 
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Materials and Methods
Patient material and informed consent
All the family members and legal patient guardians provided written 
informed consent for participation in the study, which is embedded in 
a broader study of the cause of brain malformation at the Erasmus MC. 
SNP Arrays
500 ng of total genomic DNA extracted from peripheral leucocytes of the two 
affected brothers and their unaffected sister was hybridized to Genome-Wide 
Human SNP Array 6.0 according to the manufacturer’s protocol (Affymetrix, 
Santa Clara, CA). Affymetrix Genotyping Console (GTC4.1.0) was used 
for genotyping and both GTC4.1.0 and CNAG v3.3.0.1 Beta were used for 
regions of homozygosity (ROH) analysis as well as copy number analysis7.
Whole Genome Sequencing (WGS)
DNA from the mother and two affected sons was extracted from peripheral 
leucocytes (mother) and fi broblast cell lines (sons) and sent to Complete 
Genomics (Mountain View, US), for whole genome sequencing8. This 
technique was preferred above exome sequencing in order to minimize 
the chance of missing the mutations by exon capturing techniques9.
Reads were mapped to the National Centre for Biotechnology Information 
(NCBI) reference genome, build 36. Analysis of the whole genome 
sequencing data was done using CGA tools version 1.3.0 and TIBCO 
Spotfi re version 3.3.1. The initial analysis was restricted to nonsynonymous 
variants, variants disrupting the acceptor or donor splice site or small 
insertions or deletions (up to approximately 50 bp) in the homozygous area 
that were fully called and were not present in dbSNP129, or in data from the 
1000 genome database and Exome variant sever (Washington university), 
or in 100 control samples from our in-house database (HuVariome). 
Additionally, variants should follow the expected autosomal homozygous 
recessive inheritance pattern. When this analysis did not lead to a result, 
the stringency of the fi ltering was lowered by allowing no-calls or half-
calls at potential variant positions, as long as one of the family members 
showed a variant on at least one allele. As a compound heterozygous 
recessive or X-linked inheritance could not be excluded by the pedigree 
of this family, we also performed analyses for these inheritance models. 
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Sanger Sequencing
Verifi cation of the mutation was performed by Sanger sequencing of 
exon 14 of the PNKP gene (RefSeq NG_027717) on DNA isolated from 
peripheral leucocytes. PCR amplifi cation reactions were performed and 
products were purifi ed with ExoSAP-IT (USB). Direct sequencing of 
both strands was performed using Big Dye Terminator chemistry ver. 
3.1 (Applied Biosystems). DNA fragment analysis was performed using 
capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied 
Biosystems) and the software package Seqscape (Applied Biosystems, 
version 2.1). Primer sequences are available upon request.
DNA repair and Apoptosis Studies
In cultured skin fi broblasts from patient 1 and 2, transcription-coupled 
nucleotide excision repair after UV treatment was used as diagnostic test 
for Xeroderma pigmentosum and Cockayne syndrome as described and 
resistance to inhibition of DNA synthesis after X-ray irradiation (cell cycle 
arrest) was used as a diagnostic test for mutations in the ATM pathway 
(ataxia-telangiectasia and Nijmegen breakage syndrome)10,11,12.
Using cultured skin fi broblasts from both patients bearing the homozygous 
PNKP mutation, and 5 healthy control cells lines, we tested for susceptibility 
to apoptosis. In order to detect apoptosis the cells were stained with the 
FlicaTM (Fluorescent-Labeled Inhibitor of Caspases) apoptosis multi-
caspase detection kit (Immunochemistry Technologies, LLC), which 
makes use of an inhibitor sequence of active caspases and was performed 
according to the manufacturer instructions. Fluorescent cells were scored 
(as a percentage of apoptotic fi broblasts) before and after stress induction 
by 24 hours serum deprivation and then a further 24 hours exposure to 
5 mM dithiothreitol (DTT) by two blinded investigators. Necrosis versus 
apoptosis was tested by vital staining exclusion with propidium iodide. The 
experiment was repeated three times and each time performed in triplicate. 
Quantitative PCR (qRT-PCR)
Analysis of gene expression by qRT-PCR was carried out using a KAPA 
SYBRH FAST qPCR Kit (Kapa Biosystems) in the CFX96 Real-Time 
system (BioRad). Thermal cycling conditions were as follows: denaturing 
step (95˚C for 3 minutes), followed by 35 cycles of denaturing (95˚C for 
5”), annealing and extension (60˚C for 30”). Fluorescence detection and 
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data analysis were performed by BioRad CFX Manager 2.0. Experiments 
were performed in triplicate using as the reference GAPDH (MIM 138400) 
and ACTB (MIM 102630) for gene expression normalization13. Primers are 
listed in supplemental Table S3.
Results
SNP arrays and WGS
ROH analysis of the two affected brothers and an unaffected sister 
was performed in CNAG 3.3.0.1 Beta. Two regions of overlapping ROH 
were found in the two affected brothers and not in the unaffected sister 
on chromosome 11q23 (bp 117,449,498-118,276,116, build 37) and 
chromosome 19q13 (bp 34,230,986-51,258,314, build 37). Considering 
the consanguinity loop and the size of the area (17 Mb), the region on 
chromosome 19q13 can be confi dently considered identical by descent 
rather than identical by state and would putatively contain the genetic 
mutation (Figure S1). The mapped whole genome sequence of the three 
samples (mother and two sons) varied between 183 and 192 Gb, resulting in 
a good average coverage between 66x and 68x per genome (supplemental 
Table S1). Confi dent diploid calls could be made for approximately 97% 
of the reference genome in all cases. On average, 3.75 million genetic 
variants were identifi ed per sample, including single nucleotide variants 
and short insertions, deletions and substitutions up to ~50 bp. 
Filtering for a homozygote recessive mutation present in both affected 
individuals was applied and after allowing no calls, variations in only 3 
genes in the homozygous regions were found: ZNF285A, FCGRT and 
PNKP (Figure S2). We excluded FCGRT as this encodes a protein only 
expressed in placental tissue and responsible for transferring IgG from 
mother to fetus therefore is not relevant to the phenotype. ZNF285A is 
100% identical to human gene ZNF806 and ZNF678, it has no mouse 
ortholog which throws doubt onto the physiological mechanism, and is in 
a cluster of more then 25 similar ZNF genes on chromosome 19. This 
makes it unlikely that this is the causative gene for this phenotype. 
The PNKP variant was confi rmed by Sanger sequencing, which showed 
an insertion of 17 bp corresponding to a duplication in exon 14 of PNKP 
(c.1250_1266dup) resulting in a frameshift (p.Thr424GlyfsX48, PNKP-
201 Ensembl database). This insertion is within the largest candidate 
ROH (supplemental Figure S1 and Table S1). The PNKP gene was 
recently described in literature to be related to microcephaly, seizures and 
DNA Repair and Microcephaly 83
developmental delay (MCSZ) syndrome and one of the mutations was the 
same variant that we identifi ed in our family6. Although heterozygous for 
the duplication, the mother was homozygous for the haplotype previously 
described. This confi rms the association of the duplication with this 
haplotype in different ethnic backgrounds, and suggests this haplotype 
might predispose to the occurrence of the duplication, instead of being 
a founder effect. Analysis of WGS data for compound heterozygous and 
X-linked inheritance did not lead to any additional causative variants 
being found. We also specifi cally looked into genes known to be involved 
in neuropathy (Table S4) and found suffi cient coverage and sequencing 
depth to confi dently exclude a causative mutation. 
qRT-PCR
In order to confi rm the 17 bp duplication in exon 14 and to study its effect 
on PNKP expression we studied transcripts by qRT-PCR. Using primers 
against PNKP and designed over exon 3 and 4 and exon 15 and 16 we 
showed that the expression of PNKP was consistently decreased, however 
there was still expression of mRNA for PNKP in the homozygous state 
(supplemental Figure S3). These results support the effect of the mutation 
as a loss of PNKP function.
Apoptosis Studies
One of the effects of DNA damage is that, due to overall cell stress, cells 
have an increased susceptibility to undergo apoptosis. It has also been 
hypothesized that abnormal apoptosis is the pathogenic mechanism 
leading to microcephaly in MCSZ6. Cultured skin fi broblasts from both 
patients had indeed a signifi cantly increased tendency to undergo apoptosis 
(Student’s unpaired t-test p<0.0001) when under stress conditions in 
comparison to 5 control cell lines (Figure 3). 
Discussion
We successfully applied WGS to identify the disease causing PNKP 
mutations in two brothers with a novel phenotype consisting of progressive 
cerebellar atrophy, severe polyneuropathy, microcephaly, and severe ID. 
There were occasional seizures, but no history of early infantile epileptic 
encephalopathy.
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Figure 3. Patient 1 and patient 2 fi broblasts have an increased tendency to undergo 
apoptosis when treated with 5mM DTT in comparison to 5 control cell lines, each experiment 
involved testing 5 control cell lines and 2 patient cell lines on 3 separate occasions. 
(p<0.001, unpaired t-test, SPSS v17.0). Rates are shown as a mean of 3 experiments 
(+/- SEM).
The same 17 bp duplication in exon 14 (c.1250_1266dup, resulting in 
a frame shift Thr424GlyfsX48) in PNKP in homozygous and compound 
heterozygous state has been identifi ed in patients with a different 
syndrome (MCSZ/EIEE10, microcephaly, intractable seizures and 
developmental delay syndrome)6. The published three patients who 
were homozygous for this mutation within an identical haplotype were 
not described as having progressive neurodegeneration. However, our 
patients clearly showed progressive disease in childhood, with loss of 
motor milestones (see supplemental video), development of severe 
neuropathy and cerebellar atrophy. The MCSZ syndrome was not 
considered in our patients because of these symptoms. The extensive 
diagnostic investigations, the combined autozygosity mapping and WGS 
approach makes very unlikely that in this family we missed another 
genetic mutation accounting for the disorder.
PNKP is a dual function protein that has a polynucleotide 3’phosphatase 
and a polynucleotide 5` hydroxylkinase domain and has an important 
role in repair of both single strand breaks (SSB) and double-strand 
breaks (DSB)14,15. Fibroblast cell lines from our PNKP patients showed an 
increased tendency to go into apoptosis, supporting a role of apoptosis 
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in the pathogenesis. Our observations suggest that stress placed on the 
cell by the DNA repair defect causes insuffi cient proliferation and cell 
death. Increased apoptosis was shown in mouse neuronal precursors and 
differentiated neurons with reduced Pnkp levels6.
We looked at PNKP’s interacting partners using STRING analysis, 
which combines information from different sources to identify known and 
putative protein interactions (Figure 4). This shows interaction with known 
neurodegenerative disease-associated proteins (Figure 4). Mutations 
Figure 4. STRING analysis showing PNKP interactions between known proteins which are en-
coded by genes associated with primary microcephaly syndromes (red fi lled circles), DNA repair 
disorders (green fi lled circles), proteins not yet associated with human neurological disease 
(candidate genes, blue fi lled circles). The blue line between the proteins indicate known interac-
tions and the thickness of the line is representative of the confi dence of evidence (the thicker the 
line, the more evidence to support the interaction).
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in TDP1 cause autosomal recessive spinocerebellar ataxia with axonal 
neuropathy (SCAN1, MIM 607250)16, and this has led to the previous 
suggestion that PNKP could be a gene for SCAN17. APTX mutations cause 
ataxia-oculomotor apraxia type 1 (AOA1, MIM 606350). PNKP, TDP1, and 
APTX defects all lead to abnormal SSB repair, which provides experimental 
evidence for a common mechanism of neurodegeneration18. 
Severe microcephaly is observed in the autosomal recessive primary 
microcephaly syndromes (MCPH). One of the genes involved in this 
disorder, MCPH1, links the MCPH genes to DNA repair by activating ATM 
and ATR (respectively associated with ataxia-telangiectasia and Seckel 
syndrome)14,19, which in turn phosphorylate and activate PNKP.
In the DSB repair, which is particularly important in dividing cells during 
development, PNKP directly interacts with the scaffold XRCC4 and activates 
LIG4. LIG4 mutations cause immunodefi ciency with microcephaly (MIM 
606593)19,20. DNA ligase 4 -/- mice show increased apoptosis throughout 
the nervous system and die in the embryonic period. Lig4 conditional KO 
mice (Lig4 Nes-Cre) have a pronounced microcephaly and show increased 
apoptosis from E13.5, peaking at E1521. This apoptosis is apparently 
mediated by the intact pro-apoptotic function of ATM in Lig4 mutants22. 
Microcephaly due to increased apoptosis of neuroprogenitors during 
embryonic development has been shown by our group in a syndrome with 
congenital microcephaly and diabetes23.
Therefore, the function and interactions of PNKP supports a role in the 
neurodegenerative phenotype as well as microcephaly, possibly by 
increased apoptosis.
In conclusion, we have described a neurodegenerative phenotype not 
previously described with PNKP mutations and used a combined approach 
of autozygosity mapping and whole genome sequencing as a valuable tool 
for diagnosis. 
Acknowledgements
We thank Dr N.G. Jaspers at the department of Genetics, Erasmus 
Medical Center for critically reading the manuscript. We acknowledge 
the collaboration of the members of the patients’ family. We thank J. 
Meulstee for help with interpretation of EMG data. We also thank Tom 
de Vries Lentsch for the fi gures and Petra Veraart for the genealogical 
study.
DNA Repair and Microcephaly 87
Ta
bl
e 
1.
 N
er
ve
 c
on
du
ct
io
n 
ve
lo
ci
tie
s 
an
d 
E
M
G
 re
su
lts
 o
f b
ot
h 
pa
tie
nt
s.
EM
G
 P
ati
 e
nt
 1
 (1
1 
ye
ar
s)
M
ot
or
 n
er
ve
 
M
us
cl
e
D
M
L
N
CV
SN
A
P
CM
A
P:
 d
is
ta
l 
sti
 m
ul
ati
 o
n
CM
A
P:
 p
ro
xi
m
al
 
sti
 m
ul
ati
 o
n
R 
an
t ti
 b
ED
B
10
.4
 m
s
72
 m
/s
0.
4 
m
V
0.
6 
m
V
R 
m
ed
ia
n
A
PB
3.
5 
m
s
41
 m
/s
5.
0 
m
V
4.
5 
m
V
EM
G
 P
ati
 e
nt
 1
 
(1
6 
ye
ar
s)
R 
ti b
 a
nt
ED
B
0 
m
V
R 
po
st
 ti 
b
A
H
0 
m
V
L 
po
st
 ti 
b
A
H
0 
m
V
R 
m
ed
ia
n
A
PB
5.
3
34
 m
/s
4.
5 
m
V
2.
1 
m
V
Se
ns
or
y 
ne
rv
e
L 
su
ra
l
0 
uV
R 
m
ed
ia
n 
(d
ig
it 
3)
0 
uV
N
ee
dl
e 
EM
G
FP
PS
W
M
ax
im
al
 
pa
tt 
er
n
Po
ly
ph
as
ic
 M
U
A
P
L 
TA
+
+
0
L 
Q
+
-
m
ix
ed
+
EM
G
 P
ati
 e
nt
 2
 
(1
1 
ye
ar
s)
M
ot
or
 n
er
ve
 
M
us
cl
e
D
M
L
N
CV
SN
A
P
CM
A
P:
 d
is
ta
l 
sti
 m
ul
ati
 o
n
CM
A
P:
 p
ro
xi
m
al
 
sti
 m
ul
ati
 o
n
 Chapter 388  
R 
an
t ti
 b
ED
B
0 
m
V
0 
m
V
R 
po
st
 ti 
b
A
H
6.
5 
m
s
34
 m
/s
2.
8 
m
V
1.
5 
m
V
L 
po
st
 ti 
b
A
H
4.
9 
m
s
37
 m
/s
2.
7 
m
V
2.
4 
m
V
Se
ns
or
y 
ne
rv
e
L 
su
ra
l n
er
ve
0 
uV
N
ee
dl
e 
EM
G
FP
PS
W
M
ax
im
al
 
pa
tt 
er
n
Po
ly
ph
as
ic
 M
U
A
P
L 
ti b
 a
nt
-
-
m
ix
ed
-
EM
G
 P
ati
 e
nt
 2
 
(1
6 
ye
ar
s)
M
ot
or
 n
er
ve
 
M
us
cl
e
D
M
L
N
CV
SN
A
P
CM
A
P:
 d
is
ta
l 
sti
 m
ul
ati
 o
n
CM
A
P:
 p
ro
xi
m
al
 
sti
 m
ul
ati
 o
n
R 
ul
na
r 
ne
rv
e
A
D
M
4.
4 
m
s
31
 
0.
7 
m
V
0.
8 
m
V
R 
po
st
 ti 
b
So
le
us
0 
m
V
L 
po
st
 ti 
b
A
H
0 
m
V
Se
ns
or
y 
ne
rv
e
R 
su
ra
l n
er
ve
0 
uV
R 
m
ed
ia
n 
(d
ig
it 
3)
0 
uV
N
ee
dl
e 
EM
G
FP
PS
W
M
ax
im
al
 
pa
tt 
er
n
Po
ly
fa
si
c 
M
U
A
P
R 
TA
++
-
0
R 
FR
++
++
+
0
R 
BB
-
-
m
ix
ed
+
DNA Repair and Microcephaly 89
Table 1. Nerve Conduction Velocity (NCV) and Distal Motor Latency 
(DML) values for patients 1 and 2 show slowing and loss of conduction in 
motor and sensory nerves, conduction block and denervation, consistent 
with a severe mixed demyelinating/axonal sensorimotor polyneuropathy. 
Normal values: NCV > 50 m/s in the arms, > 40 m/s in the legs; Compound 
Motor Action Potential (CMAP), Extensor Digitorum Brevis (EDB) > 5 mV; 
CMAP muscles hand > 10 mV. 
Additional abbreviations used in the table: Abductor Digiti Minimi (ADM); 
Abductor Hallucis (AH); Abductor Pollicis Brevis (APB); Biceps Brachii 
(BB); Femoris Rectus (FR); Fibrillations (FP); Motor Unit Action Potentials 
(MUAP); Positive Sharp Waves (PSW); Quadriceps (Q); Sensory Nerve 
Action Potential (SNAP);Tibialis Anterior (TA). Anterior tibial nerve (ant tib); 
posterior tibial nerve (post tib). Right Side (R); Left Side (L)
Supplemental data
Figure S1. CNAG view showing overlapping regions of homozygosity (ROH) on 
chromosome 11 and 19 among the three sibs (two affected brothers and one unaffected 
sister). The blue bar represents ROH of the unaffected sister, the red and green bars 
represent the brothers (i.e. the overlapping ROH on chromosome 8 concern the unaffected 
sister and one affected brother).The brothers share ROH on chromosome 11 and 19.
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Figure S2. Whole genome sequence analysis. Figure showing fi ltering steps starting from 
the list of variants found and leading to candidate genes. 
Figure S3. PNKP mRNA expression. qRT-PCR data of PNKP relative to the housekeeping 
gene GAPDH in fi broblasts from patient 1 and 2 and two controls, using two different primers 
(PNKP1, covering exons 3-4, and PNKP2, covering exons 15-16) showing variable, but not 
absent expression in fi broblasts.
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Table S3. Primers used for qRT-PCR experiments of PNKP.
 PNKP_qRT_1 forward GGAGCTGGTCGCAGATCCT 
 PNKP_qRT_1 reverse CCAACCCCGGCTTCAACT
 PNKP_qRT_2 forward GGCGCGCCACAACAAC
 PNKP_qRT_2 reverse CGAACTGCTTCCTGTAGCCATA
Table S4. Genes with OMIM entry which are associated with hereditary neuropathy. The 
WGS sequence data were specifi cally checked for suffi cient coverage and data quality for 
these genes; no mutations were identifi ed despite high quality data.
Gene OMIM #
GDAP1 606598
MTMR2 603557
SBF2 607697
SH3TC2 608206
NDRG1 605262
EGR2 129010
PRX 605725
FGD4 611104
FIG4 609390
MED25 610197
LMNA 150330
PMP22 601097
SLC12A6 604878
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Abstract
Primary microcephaly, defi ned as head circumference below -3 SD at 
birth, is caused by genetic mutations leading to decreased mitotic rate 
and/or accelerated apoptosis of neural progenitors. A rare cause of 
severe microcephaly is cerebro-oculo-facial-skeletal syndrome (COFS), 
characterized by a catastrophic course and early death. The question was 
raised whether insuffi cient proliferation of neural progenitors, as proposed 
for other causes of primary microcephaly with prolonged survival, would 
be suffi cient to explain the microcephaly and severe course. Mutations 
in DNA excision repair genes ERCC1, -2 (XPD), -5 (XPG), -6 (CSB) can 
cause COFS syndrome. We hypothesized that abnormal accelerated 
apoptosis would correlate with the presentation of COFS syndrome, 
compared to other DNA repair defects. We describe 7 new COFS 
individuals with ERCC5 mutations who died in infancy. Fibroblasts of 
these patients are unable to repair UV-induced DNA damage. We have 
studied tendency to apoptosis in fi broblasts derived from individuals with 
COFS syndrome and microcephaly in order to test the hypothesis that 
tendency to apoptosis correlates with a congenital microcephaly. We 
observed in the COFS syndrome cells an increased susceptibility to cell 
death under stress conditions in the absence of UV radiation as a trigger. 
Apoptotic levels correlated with the severity of microcephaly and disease 
course. Additionally, Ercc5 knockout mice showed increased apoptosis 
at 4 weeks in tissues including cerebral frontal cortex. We propose that 
primary microcephaly and lack of brain development in COFS syndrome, 
as example of severe DNA repair defect, is caused by abnormal apoptosis 
of neural progenitors, in part independent of externally (UV) induced DNA 
damage.
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Introduction
Primary microcephaly, defi ned as head circumference at birth at or below 
-3 SD of expected, is a developmental disorder often caused by genetic 
mutations, but different hypotheses have been proposed about the 
mechanism of onset. Primary microcephaly is associated with variable 
course, e.g. mild to moderate intellectual disability (ID), epilepsy and only 
mild growth delay1, or with severe neurological phenotype, progressive 
course and early death2. As a general mechanism, decreased proliferation 
of neural progenitors has been proposed, since many mutations involve 
genes responsible for regulation of mitosis3,4. Accelerated death of 
neuronal precursors leading to unscheduled apoptosis during brain 
development has also been proposed but there are very few examples 
providing evidence for this mechanism in animal models5,6,7. Another 
group of disorders variably associated with microcephaly are DNA repair 
disorders, a heterogeneous group of diseases caused by failure of one 
of the several mechanisms repairing DNA damage from endogenous 
metabolism (e.g reactive oxygen species) or from external causes 
such as irradiation, reactive chemicals etc. Some repair processes 
operate genome wide e.g global genome nucleotide repair (GG-NER) 
a multi-protein cut-and-patch repair system for a wide range of helix-
distorting lesions, including the main UV-induced DNA lesions as well as 
numerous chemical adducts. Other repair pathways are associated with 
replication and/or transcription, e.g. transcription-coupled nucleotide 
excision repair (TC-NER), which specifi cally eliminates bulky adducts 
which block ongoing transcription to allow rapid resumption of the vital 
process of gene expression8. DNA repair disorders predispose to cancer 
and immune disease, primary growth failure, neurodegeneration and 
premature aging, all generally considered consequences of loss of cell 
proliferation control8,9.
A rare, early onset DNA repair defect, cerebro-ocular-facial-skeletal 
(COFS) syndrome, presents with severe microcephaly at birth, cataracts 
and/or microphthalmia, facial dysmorphism, and arthrogryposis10. Affected 
individuals are usually small for gestational age and show failure to thrive, 
major feeding diffi culties, sun sensitivity, failure to achieve developmental 
milestones and they frequently die in early infancy because of brain stem 
failure. Brain MRI typically shows simplifi ed gyration of the cerebral cortex, 
enlarged lateral ventricles, cerebellar atrophy and delayed myelination11. 
Because of the presentation, COFS syndrome is considered to be a severe 
form of Cockayne syndrome, which has similar but milder abnormalities 
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and progresses more slowly. Based on complementation and sequence 
analysis, COFS has been associated with mutations in the same genes 
causing Xeroderma pigmentosum (XP) or Cockayne syndrome (CS)10 
(ERCC1 (excision repair cross-complementing group 1; MIM 610758), 
ERCC2/XPD (MIM 610756), ERCC5/XPG (MIM 278780), ERCC6/
CSB (MIM 214150)). Mutations in ERCC5 also cause XP, the seventh 
complementation group G (XPG)12. Approximately 30% of XPG individuals 
have a neurological phenotype13 however there is no adequate explanation 
for the difference in phenotype between CS and XP individuals. Several 
theories have been proposed including an effect of the type of mutation, 
DNA repair pathway involved and a possible role of premature death of 
neurons in the central nervous system14,15,16. 
Because of the catastrophic neurological phenotype associated with 
COFS we wondered whether the mechanism would be only related to 
insuffi cient proliferation or also to abnormal up regulation of cell death. 
For this purpose, we compared genetic mutations and susceptibility to 
apoptosis of living cells derived from seven new un-described COFS 
individuals with ERCC5 mutations, one previously reported individual 
with ERCC5 mutation and a mild neurological phenotype (XP) without 
microcephaly, and one “classic” CS individual with prolonged survival. 
Additionally we studied the occurrence of apoptosis in brains of Ercc5 
knockout mice, which show a severe phenotype comparable with COFS 
syndrome. 
Clinical Reports
The majority of the COFS individuals presented in this report have not 
been described previously. We summarize here the clinical presentation 
of these individuals.
Case 1 – Individual FL 10E425.
The proband is the 2nd child of non-consanguineous Dutch parents. 
She was noted to have poor foetal growth at gestational week (GW) 26; 
amniocentesis showed normal female karyotype and fetal brain scans noted 
large ventricles and a small cerebellum. Examination at birth (37+4 weeks) 
showed a birth weight of 2105g, occipito-frontal circumference (OFC) of 
30.4cm (-3SD), mild to moderate contractures of the major joints, facial 
dysmorphism with a sloping forehead, deep set eyes, micrognathia, broad 
nasal bridge and short palpebral fi ssures. Ophthalmological examination 
revealed no cataracts but pale optic discs, brainstem auditory evoked 
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response (BAER) revealed maximal perceptive deafness. She made 
no neurological progress and was naso-gastric (NG) tube-fed. A brain 
MRI showed enlarged ventricles, simplifi ed gyral pattern of the cortex, 
hypoplastic corpus callosum, cerebellar vermis, cerebellar hemispheres, 
pons, optic nerves and lack of myelination (Figure 1A+B). She showed 
irregular respiration and died suddenly at 2 months of age.
Case 2 – Individual Y 94E0106. Clinical data of this individual have 
already been published by Hamel et al 17. 
Case 3 – Individual L 96E116. The male proband is the fi rst child 
of consanguineous Moroccan parents, born at 38 weeks gestation 
by caesarean section. During pregnancy growth retardation and 
oligohydramnios were noticed. Examination at birth showed microcephaly 
(OFC 30.1 cm -3SD), birth weight 1750 g, micrognathia with a high palate 
and fl exion contractures of knees, ankles, wrists and elbows. Feeding 
diffi culties were present from birth on; he was NG tube-fed. Due to feeding 
problems and frequent respiratory tract infections he was hospitalized 
from birth until age 3 months. He had seizures from age 4 months. 
Ophthalmological examination showed severe cataract in both eyes. A CT 
scan of brain revealed agenesis of the corpus callosum. He died at age 8 
months.
Case 4 – Individual AA 01E0092 First pregnancy of consanguineous 
Moroccan parents. Examination at birth showed microcephaly (-3SD) 
with dysmorphic features; small deep set eyes, contractures of major 
joints and fl exure contractures of fi ngers, and bilateral cataracts. He was 
NG tube- fed and at 1 month developed epilepsy. EEG showed focal 
right temporal irritability with secondary generalisation. By 5 months of 
age, OFC was -8 SD, he had made no neurological progress, had had 
several episodes of pneumonia and required home oxygen. MRI revealed 
a small cerebellum, large retro-cerebellar space, supratentorial reduced 
gyration, and subtle calcifi cation in the thalami. He died at 8 months of 
age of pneumonia.
Case 5 – Individual H.A 02E0682 Brother of case 4, 2nd child born 
at 42/40 GW; at birth HC was 31.5cm (-3SD) with dysmorphic typical 
facial features, arefl exia and joint contractures. He died at 26 days of 
pneumonia.
Case 6 – Individual S 07E0874. Female infant, at the 20 week routine 
ultrasound, showed microcephaly (-2.5SD). Examination shortly after 
birth showed bilateral microphthalmia, cataracts, short neck, small 
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thorax, contractures of thumbs, elbows, knees and hips and vertical talus. 
Dysmorphic features were short, sloping forehead, prominent nose, and 
long fi ltrum. Hypertonia of the limbs with hypotonia of the thorax and 
neck. She developed progressive failure to thrive, swallowing diffi culties 
requiring tube feeding, bilateral perceptive deafness and epileptic spasms 
with hypsarrythmia on EEG. Brain MRI at 4 months of age showed 
hypoplasia of the cerebellar hemispheres and brain stem, normal pons, 
simplifi ed gyration of the cerebral cortex, dilated lateral ventricles, 
decreased myelination with thin corpus callosum (fi gure 1C+D). She died 
of respiratory insuffi ciency at 17 months.
Case 7 – Individual M 00E0656. Examination after birth showed a female 
infant with OFC of 29.5cm (-2.5SD), hypertonia, small thorax, contractures 
of wrists and ankles, microphthalmia, cataract, neck and axial hypotonia. 
She had vesicoureteral refl ux. By 11 months of age she exhibited 
progressive feeding and respiratory problems and epileptic spasms 
with hypsarrythmia on an EEG. Brain MRI at 5 months showed diffuse 
cerebral atrophy and lack of myelination of the white matter, thin corpus 
callosum, and progressive dilatation of the lateral ventricles. She died at 
approximately one year of pneumonia.
Case 8 – Individual D, 96E1041. 2nd child of non-consanguineous parents 
(previous healthy older brother). At birth the female infant was noted to 
be dysmature, microcephalic (-3SD) with contractures of major joints 
and congenital cataracts. At 2 years of age she could roll from back to 
front and most of nutritional intake via a gastrosomy. On examination she 
was microcephalic (-8SD), with central hypotonia, lack of spontaneous 
movements, progressive contractures of hips and knees and fi ngers, 
she did not respond to light and required hearing aids. She had repeated 
admissions due to feeding diffi culties, gastro-oesophageal refl ux and 
aspiration pneumonias. She developed infantile spasms and absence 
seizures.EEG showed sporadic epileptic activity with an abnormal 
background. EMG showed polyneuropathy MRI showed generalised 
widened ventricular system, thin corpus callosum, hypoplasia of inferior 
vermis and diffuse hypomyelination. Clinical information indicates survival 
at least until the age of 4 years.
Case 9 – Individual H, 80E163.This individual with an ERCC5 mutation 
had short stature, bird like face, sensorineural hearing loss, laryngeal 
dystonia and peripheral neuropathy with a mild clinical course. The clinical 
presentation has been described as the XP-G individual (case 15) by 
Anttinen et al in 200812.
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Figure 1. MRI of individuals 1 and 6A and B: MRI head of individual 1 performed at 
approximately 1 month of age. 1A: Sagittal T1 weighted view shows simplifi ed gyral pattern 
of the cortex, normal corpus callosum, hypoplasia of the cerebellar vermis, hemispheres 
and pons. 1B: T1 weighted transversal view showing enlarged lateral ventricles, cavum 
septum pellucidum and simplifi cation of the gyri.C and D: MRI head of individual 6 at 
approximately 4 months of age. 1C: T1 coronal weighted view showing hypoplasia of the 
inferior vermis and simplifi ed gyri. 1D: T2 weighted transversal view showing enlarged 
lateral ventricles and simplifi ed gyral pattern.
Materials and Methods 
DNA repair studies and genotyping
GG-NER) and TC-NER were assayed in cultured skin fi broblasts from 
affected individuals and controls according to Jaspers et al.18. In these 
tests, XP and CS individuals show the same abnormalities as COFS18. 
After a specifi c NER defect was identifi ed, cells were complemented with 
fi broblasts of individuals with known mutations and classifi ed according 
to their complementation group19. Subsequently the genes were Sanger-
sequenced according to their complementation group, with the exception 
of case 8. 
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Apoptosis Studies 
Using cultured skin fi broblasts from case 1-7 (COFS), one individual with 
ERCC6 mutation and a neurological phenotype (Case 8), one individual 
with ERCC5 mutation and a mild non-neurological phenotype (Case 
9) and as a positive control, fi broblasts from an individual with a PNKP 
mutation7 and fi broblasts from an individual with confi rmed IER3IP1 
mutation5 and 5 healthy control cell strains, we tested for susceptibility to 
apoptosis. Apoptosis was detected in cells by staining with the FlicaTM 
(Fluorescent-Labelled Inhibitor of Caspases) apoptosis multi-caspase 
detection kit (Immunochemistry Technologies, LLC), which makes use of 
an inhibitor sequence of active caspases and was performed according 
to the manufacturer instructions. Percentage of apoptotic cells were 
calculated by scoring fl uorescent cells before and after stress induction 
by 24 hours serum deprivation and then a further 24 hours exposure to 
5 mM dithiothreitol (DTT) by two blinded investigators. Necrosis versus 
apoptosis was tested by vital staining exclusion with propidium iodide. The 
experiment was repeated three times and each time performed in triplicate. 
Mouse Studies 
The generation and characterization of a new, bona fi de Ercc5 (Xpg) knockout 
mice, which accurately recapitulate the DNA repair defects of the human 
disease and closely mimic many clinical symptoms of the severe form of ERCC5 
defects in patients will be described in a separate publication (Barnhoorn et al., 
submitted). All animals were of the same F1 C57BL6J/FVB hybrid background 
and had ad libitum access to standard mouse food (CRM pellets, SDS BP 
Nutrition Ltd; gross energy content 18.36 kJ/g dry mass, digestible energy 
13.4 kJ/g) and water. The experiments were performed in accordance with the 
Principles of Laboratory Animal Care (NIH publication no. 86-23) and with the 
guidelines approved by the Erasmus University Animal Care Committee.
Histological procedures
Mice were anesthetized with pentobarbital and perfused transcardially with 
4% paraformaldehyde. The brain was carefully dissected out and fi xed 
overnight in 4% paraformaldehyde. Routinely, brain tissue was embedded 
in 10% gelatine blocks, rapidly frozen, and sectioned at 40 μm with 
a freezing microtome or stored at -80°C until use. Sections were processed, 
free-fl oating, using a standard avidin– biotin–immunoperoxidase complex 
method (ABC, Vector Laboratories, Burlingame, CA) with diaminobenzidine 
(0.05%; Sigma) as the chromogen. 
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Alternatively, brain specimens were fi xed overnight in 10% buffered formalin, 
paraffi n-embedded, sectioned at 5 μm, and mounted on Superfrost Plus 
slides. For immunohistochemistry, paraffi n sections were deparaffi nized, 
rehydrated in decreasing concentrations of ethanol, treated with 10 mM 
sodium citrate buffer, pH 6, in the microwave for antigen retrieval, and 
further processed using the ABC method. 
A series of paraffi n sections were employed for TdT-mediated dUTP 
Nick-End Labeling (TUNEL) assay using a commercial kit (Apoptag 
Plus Peroxidase in situ apoptosis detection kit, Millipore). Sections were 
deparaffi nized and incubated as described by the manufacturer.
Primary antibodies (supplier; dilutions) used in this study were rabbit 
anti-p53 (Leica; 1:1000) and rat anti-Ki67 (Dako; 1:200). Biotinylated 
secondary antibodies from Vector Laboratories were used in a 1:200 dilution. 
Levels of p53 were assessed using gelatin sections, whereas TUNEL and 
Ki-67 was determined on paraffi n sections using 4 animals per group. 
Immunoperoxidase-stained sections were analysed and photographed 
using an Olympus BX40 microscope and a ColorView digital camera. 
Results
DNA repair
Fibroblasts from Cases 1-9 were tested for various nucleotide excision repair 
(NER) endpoints using UV as a source of DNA damage including sensitivity 
to UV light. Both GG-NER and TC-NER were grossly abnormal in COFS 
individuals (1 -7). Cells from the CS individual 8 show as expected a strongly 
reduced (albeit not completely absent) TC-NER activity and normal GG-NER 
in the wild type range, i.e. normal transcription-independent DNA repair. In 
individual 9 (XP) only GG-NER was tested and was defi cient (Table 1). 
Sequencing/Complementation Analysis
The ERCC5 mutations in individuals 1-7 and other affected individuals are 
presented in table 2. The results indicate that all the COFS individuals had 
a biallelic frame-shift mutation in ERCC5, among these the p.925fs55X 
being a well-known Moroccan founder mutation17. Case 1 showed a deletion 
in exon 11 at position 811 (p.Ser811f521X) and a second mutation was 
found in cDNA on qRNA – deletion of 16 nucleotides in the terminal part of 
exon 9 resulting in a frameshift from Gln729 (p.Gln729fs11X). 
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The missense ERCC5 mutation (case 9) with milder XP phenotype has 
been reported earlier12. The cells bearing mutations in IER3IP1 and PNKP 
have been previously reported5,6.
Apoptosis experiments in individual fi broblasts 
We tested in vitro susceptibility to apoptosis on cells from individuals 1-9. As 
a positive control we used cells from an individual bearing PNKP mutation6 
and cells bearing an IER3IP1 mutation5, which had previously been shown 
to have an increase tendency to apoptosis. We found that cells from 
individuals with ERCC5 mutations, microcephaly and severe neurology 
had an increased tendency to undergo apoptosis (fi gure 2A). In case 8 who 
has severe neurology and ERCC6 mutation, and case 9 (ERCC5 mutation 
and normal head circumference) apoptosis levels were similar to control 
fi broblasts. Notwithstanding the limited number of individual cell lines, this 
data suggests a clear correlation between the tendency of the cells to 
undergo apoptosis in vitro, the type of mutation, the residual DNA repair 
activity and the severity of the clinical presentation. Without DTT treatment 
the levels of apoptosis were low and there was no signifi cant difference 
between all cells lines. Considering the extreme susceptibility of ERCC5 
fi broblasts to X-radiation and UV we could not test apoptosis after irradiation. 
Similarly mouse embryonic fi broblasts (MEFs) from knockout mice did not 
survive long enough to be tested for apoptosis (data not shown). 
Ercc5 KO mouse studies 
The data from the human cells is suggestive, but does not demonstrate 
the role of abnormal apoptosis during brain development. Since data from 
human brain is lacking, we decided to investigate the developing brain 
of a mouse model displaying striking similarity to the human ERCC5 
phenotype, including progressive neurological abnormalities reminiscent 
of severe ERCC5 patients (Barnhoorn et al., submitted).
Ercc5 (Xpg) knockout mice have a tendency to slightly lower brain weights 
at postnatal day one, mimicking COFS (unpublished data). We tested levels 
of spontaneous apoptosis in these animals and observed a signifi cant 
increase in apoptotic cells in the frontal cortex at the age of 4 week as 
shown by positive staining for TUNEL and p53 (fi gure 2B and 2C). This 
was also observed in other regions of the central nervous system, including 
cerebellum and retina (Barnhoorn et al., submitted). No difference in Ki-
67 staining was observed (fi gure 2D), suggesting normal cell proliferation 
levels between Ercc5 knockout mice and littermate controls.
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Figure 2. Test for apoptosis in fi broblasts and mouse brain Figure 2: A: apoptosis in 
DTT treated fi broblasts. Individuals 1-7 who exhibit signs of COFS syndrome and have 
a homozygous XPG mutation (see Table 2). Fibroblasts have an increased tendency to 
apoptosis. Fibroblasts from individual 8 with Cockayne syndrome (CSB complementation 
group) had a lower level of apoptosis, in the control range. Fibroblasts from individual 9 
with XPG mutation and no microcephaly exhibited levels of apoptosis just above the control 
range. All apoptosis is tested after treatment with 5mM DTT in comparison to 5 control cell 
lines and two positive control fi broblasts (individuals with a PNKP and IER3IP1 mutations 
respectively) on three separate occasions. Rates are shown as a mean of three experiments 
(+/- SEM); signifi cant differences (*, p<0.05) were calculated by the Student T test. Without 
DTT provocation apoptosis levels were between 6-10% for patients and controls. 
B: Quantifi cation of TUNEL-positive cells per cm2 in frontal cortex sections of 4 weeks old 
XPG-/- and WT mice. Error bars indicate SEM; signifi cant differences (**, p<0.01) were 
calculated by the Student T-test; n=4 animals/group.
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Discussion
DNA repair disorders are clinically heterogeneous and neurological 
features are common. A diverse range of DNA repair defect disorders can 
be associated with microcephaly i.e. COFS syndrome, Nijmegan Breakage 
Syndrome (NBS, MIM 251260), Fanconi Anemia (FA, MIM 227650), Bloom 
Sydrome (BS, MIM 210900), Ligase 4 syndrome (LIG4 syndrome MIM 
606593), CS and more recently Microcephaly, seizures and developmental 
delay (MCSZ syndrome caused by mutations in PNKP, MIM 613402)7. 
Some DNA repair disorders mostly exhibit a primarily neurodevelopmental 
phenotype (NBS, COFS), others a neurodegenerative phenotype, e.g. 
CS, spinocerebellar ataxia-neuropathy type 1 (SCAN1, TDP1 mutation, 
MIM 607250). Microcephaly is common in disorders with a developmental 
phenotype. 
However, some DNA repair disorders, such as MCSZ, present with 
both a congenital microcephaly and a degenerative phenotype6. The 
pathogenesis of congenital microcephaly is commonly ascribed to 
insuffi cient neuroprogenitors proliferation, because of mitotic dysregulation 
by the centrosome20,21,22. Microcephaly caused by DNA repair disorders 
might represent an exception to this general rule. COFS syndrome presents 
with congenital microcephaly and severe neurological course leading 
to early death. As COFS can be a manifestation of severe mutations in 
XP/CS genes, such as ERCC1, ERCC2, ERCC5 and ERCC6, the same 
mechanisms playing a role in the pathogenesis of neurological symptoms 
in Xeroderma Pigmentosum and Cockayne Syndrome could be causative. 
In 1978, XP fi broblasts strains showed sensitivity to UV radiation by losing 
ability of colony formation after irradiation, the sensitivity correlating with 
the degree of neurological symptoms and type of presumed genetic 
mutation15. These and other authors assumed the mechanism to be 
a lack of protection against premature neuronal death as an explanation 
of neurodegeneration12,15. The accumulation of unrepaired DNA oxidative 
lesions in brain has been claimed to be the mechanism leading to 
progressive neuronal death and neurodegeneration in XP individuals23. 
Both arrest of normal cell cycle i.e. proliferation and activation of cell 
death cascade could be responsible for the developmental defects, such 
as microcephaly in COFS syndrome. In MCPH1 mutation, one of the 
autosomal recessive primary microcephalies, such a dual mechanism 
probably underlies the pathogenesis of microcephaly21,24,25,26. We observed 
an abnormal susceptibility to apoptosis of cells derived form individuals 
with COFS syndrome caused by ERCC5 mutations. In COFS syndrome 
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a defective proliferation is not supported by the data we have from the 
Ercc5 mouse model, which shows no difference in proliferation between 
the knockout mouse and the wild type, suggesting the predominant 
mechanism is increased apoptosis.
There are several links, which could explain the onset of microcephaly 
as consequence of abnormal apoptosis, although the mechanism leading 
to premature cell death might be different in each DNA repair disorder. 
PNKP mutations determine early apoptosis of neural progenitors7. The 
PNKP enzyme has a dual function as a polynucleotide 3’ phosphatase 
and a polynucleotide 5’ hydroxykinase, remodelling both the 5’ and 3’ end 
of damaged DNA and binding to XRCC1, one of the effectors of BER27. 
PNKP is activated and recruited by ATM and ATR. PNKP is also involved in 
the repair of double-strand breaks (DSB) related to non-homologous end 
joining (NHEJ) occurring during mitosis. DSB repair is particularly important 
in dividing cells during development. In this pathway PNKP protein directly 
interacts (via the third forkhead domain) with the scaffold XRCC4 and 
activates LIG427,28. Human mutations in LIG4 and ATR (Microcephalic 
primordial dwarfi sm type 1, MPD 1, Seckel syndrome type 1, MIM 210600) 
are causative of syndromes with primary microcephaly. Lig4 knockout 
mice have also shown abnormal apoptosis in the brain29.
The observation of DNA repair defects in primary microcephaly syndromes 
such as Seckel syndrome type 1, MCSZ and correlation to abnormal 
apoptosis as the pathogenic mechanism, triggered us to test cells from 
a larger series of individuals with COFS syndrome and corresponding valid 
animal models. Most of the available cell strains were from individuals 
belonging to the XPG/ERCC5 group. ERCC5 protein is important for DNA 
repair and is responsible for the 3`incision in Nucleotide Excision Repair 
(NER) via both the global genome repair (GGR) and transcription coupled 
repair (TCR) pathways30. ERCC5 directly interacts with the other XP 
proteins such as ERCC1 and ERCC4, which are also associated with COFS 
syndrome. The NER pathway is an important excision pathway for removing 
mutations derived from a broad range of insults. ERCC5 (XPG) alone with 
ERCC6 (CSB) may also have a role in base excision repair processes 
which is used to repair oxidative damage which could help explain why 
developing neurons are preferentially affected31. Additionally, ERCC5 has 
been suggested to be a negative regulator of apoptosis and ERCC5 mutant 
cell strains are more susceptible to apoptosis upon UV irradiation than other 
DNA repair defective cells32. However, apoptotic response of ERCC5 mutant 
cells did not seem to depend on the extent of unrepaired DNA damage33. 
Here we show increased susceptibility to apoptosis in vitro in cells from 
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ERCC5 individuals, through activation of multiple caspases (among which 
caspase 3 and 9), upon low doses of the cysteine reducing agent DTT, but 
without the UV trigger, suggesting an intrinsic vulnerability of these cells. We 
also observe a correlation between this susceptibility and the most severe 
neurological phenotype, including congenital microcephaly and early death, 
although the numbers of cell lines tested is limited. This is similar to earlier 
observation of sensitivity to UV radiation and capacity of colony formation15. 
Additionally, in strong support of this interpretation elevated apoptosis levels 
were observed ex vivo by both TUNEL and p53 staining in developing 
brains of mouse models for COFS in the Ercc5 knockout mice, whereas cell 
proliferation remains unaffected in these animals. 
We therefore hypothesize that in COFS syndrome the mechanism leading 
to neuronal death and insuffi cient brain growth, i.e. microcephaly, as well as 
insuffi cient maintenance of neural lineages after birth, i.e. neurodegeneration, 
might be abnormal up regulation of apoptosis. Accelerated neurodegeneration 
is associated with DNA repair defects that present after a normal 
developmental phase and is thought to be due to increased cell loss due to 
a defective NER/TCR pathway. The exact pathway is unclear but Ercc1 KO 
mice have been shown to exhibit slow and progressive neurodegeneration 
as well as increased cell loss in the cortex and hippocampus with increased 
p53 and caspase staining indicating an increase in apoptosis of the 
neurons34. It is therefore possible that upregulation of apoptosis in COFS 
syndrome contributes to both developmental abnormalities i.e. microcephaly 
and accelerated neurodegeneration leading to early demise.
It will be interesting in the future to study to which extent, in this and other 
DNA repair disorders, apoptosis plays a role in the onset of primary growth 
defects such as microcephaly and which apoptotic pathways are triggered 
by these mutations and which combination of factors determines the 
clinical variability and progression. 
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Tabl e 1. Biochemical DNA repair tests (global NER and transcription-coupled NER) in 
fi broblasts from seven COFS syndrome individuals, a Cockayne syndrome (CS), an XP 
individual and control cell strains. 
Individual/
complementati on 
group
Cell Line
Global NER
Unscheduled DNA synthesis
(Nuclear 3H-thymidine 
incorporati on aft er 17h)
Transcripti on
-coupled NER
(DNA synthesis 17h aft er UV 
irradiati on, 3J/m2
  1 COFS/XPG 10E425 6% 8%
  2 COFS/XPG 94E106 4% 19%
  3 COFS/XPG 96E116 4% 13%
  4 COFS/XPG 01E0092 14% 8%
  5 COFS/XPG 02E0682 9% 5%
  6 COFS/XPG 07E0874 9% 6%
  7 COFS/XPG 00E0656 2% 9%
  8 CS/CSB 96E1041 67% 24%
  9 XP/XPG 80E0163 4% Not determined
10 Control range N=50 50-80% 100%
Table 2. Mutations in affected individuals at amino acid level.
Indi-
vidual
Cell line Diagnosis/phenotype Gene Mutati on Ref
1 10E425
COFS Microcephlay at birth (-3 SD)
Died at 2 months
ERCC5 
(XPG)
p.Ser811Valfs21X 
/p.Gln729Argfs11X
This 
paper
2 94E0106 
COFS (XP/CS)
Died at 7 months
Microcephaly at birth (-3SD))
ERCC5 
(XPG)
p.Pro925Profs55X
Hamel et 
al [17]
3 96E0116 COFS
ERCC5 
(XPG)
p.Pro925Profs55X
This 
paper
4 01E0092
COFS Microcephaly at birth
Epilepsy, died at 8 months
ERCC5 
(XPG)
p.Pro925Profs55X
This 
paper
5 02E0682
COFS Microcephaly at birth, 
respiratory diffi  culti es, died at 26 days
ERCC5 
(XPG)
p.Pro925Profs55X
This 
paper
6 07E0874 
COFS Microcephaly at birth (2.5SD)
Epilepsy, died at 16 months
ERCC5 
(XPG)
p.Pro925Profs55X
This 
paper
7 00E0656 
COFS Microcephaly at birth (-2.5SD)
Epilepsy, died at 11 months
ERCC5 
(XPG)
p.Pro925Profs55X
This 
paper
8 96E1041
CS with neurological phenotype, 
microcephaly (-3SD), feeding diffi  -
culti es, severe developmental delay
ERCC6 
(CSB)
Result based on 
complementati on 
analysis
This 
paper
9 80E0163 
XP (short stature, deafness, 
peripheral neuropathy, mild course, 
no tumours)
ERCC5 
(XPG)
p.Gly766X/
p.Ala1018Metf s1X 
Antti  nen 
A et al 
[12]
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Abstract
Mutations in WDR62 are associated with primary microcephaly; however 
they have been reported with wide phenotypic variability. We report three 
individuals with novel WDR62 mutations who illustrate this variability. 
One lacks neuromotor development and has severe pachygyria on MRI, 
another has only delayed speech and motor development and moderate 
polymicrogyria, and the third has an intermediate phenotype. We observed 
a rare copy number change of unknown signifi cance, a 17q25qter 
duplication, in the severely affected individual. The 17q25 duplication 
included an interesting candidate gene, tubulin cofactor D (TBCD), crucial in 
microtubule assembly and disassembly. Sequencing of the non-duplicated 
allele showed a TBCD missense mutation, predicted to cause a deleterious 
p.Phe1121Val substitution. Sequencing of a cohort of fi ve individuals with 
WDR62 mutations, including one with an identical mutation and different 
phenotype, plus twelve individuals with clinical microlissencephaly and 
another individual with mild intellectual disability (ID) and a 17q25 duplication, 
did not reveal TBCD mutations. Although defi nitive evidence is lacking, it is 
possible that additional genetic factors contribute to modify and aggravate 
the WDR62 phenotype; Additional observations are needed to confi rm 
whether TBCD is one of these factors. 
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Microcephaly is defi ned as a head circumference of more than 3 SD below 
the expected for age and sex. Primary microcephaly is a developmental 
defect that can present with a normal or simplifi ed gyral pattern of the 
cerebral cortex (MSG), thickened cortex (microlissencephaly, MLIS) 
or disorganized cortex (e.g. polymicrogyria, MIC+PMG). Primary 
microcephaly with a normal or thin cortex, has been described as an 
autosomal recessive disorder (MCPH) based on mutations in at least 
eight genes (MCPH1, WDR62, CDK5RAP2, ASPM, CENPJ, STIL, 
CEP135 and CEP152)1. ASPM and WDR62 account for approximately 
50% of the diagnoses2. There is usually no clinical heterogeneity among 
patients with MCPH; a phenotype of near normal motor development 
with moderately compromised cognition, although epilepsy has been 
reported3. The genes mutated encode a diverse range of proteins 
but with the majority involved in centrosomal function which leads to 
decreased proliferation of neural progenitors4. Major exceptions to the 
phenotypic similarity are the disorders associated mutations in WDR625. 
Next-generation sequencing has identifi ed mutations in WDR62 in 
patients who would not have previously been grouped together for 
linkage studies5,6. 
WDR62 contains fi fteen WD-type repeat domains typical for cytoskeleton 
interacting proteins7. Although function is unknown, it is expressed 
transiently in the neocortex during the period of neurogenesis in 
a pattern identical to ASPM6. Some authors have shown WDR62 to 
be associated with spindle poles during mitosis and to have cell cycle-
dependent localization8,9,10, implying a role in centrosomal function. 
Unlike the mutations in other MCPH genes, missense and null mutations 
in WDR62 are distributed throughout the gene6,8,10,11. Additionally, 
WDR62 mutations are associated with disorders of neuronal migration 
(lissencephaly) and cortical organization (polymicrogyria), and the 
degree of intellectual disability in patients is extremely variable (table 
1)6,8,10,11. The difference in phenotype has been proposed by Nicholas 
et al. to be due to the type of mutation; with nonsense mutations 
leading to a more severe phenotype 8. However, this correlation is not 
borne out since many of the nonsense mutations described cause mild 
phenotypes and some patients with missense mutations have very 
severe phenotypes (table 1)5,6,10.
Murdock et al. proposed that the difference could be explained by 
environmental factors (e.g maternal diabetes) or by additional mutations 
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identifi ed by whole exome sequencing (GLI2 and KIAA1598) that provide 
an additive effect in the patients with abnormal cortical architecture 
and a more severe phenotype11. The use of comparative genome 
hybridization (CGH) has generated much data about copy number 
variation (CNVs), which harbour genes causative of syndromic and non-
syndromic intellectual disability (ID)12. Similarly a large number of rare 
CNVs of unknown signifi cance have been detected in ID individuals, 
classifi ed as variants of unknown signifi cance (VUS). In the clinical 
setting, fi nding a VUS does not usually explain the phenotype, however 
it can be contributory12. Additionally, it is possible that an uncommon 
variation unmasks a recessive disorder with a pathogenic mutation on 
the other allele13. 
We observed three individuals with primary microcephaly and novel 
WDR62 mutations, greatly differing in their clinical presentation, 
one with an atypically severe phenotype (individual 1). We tested 
the hypothesis that additional factors contribute to the phenotypic 
variability. The detailed clinical presentation is described in the 
supplemental data. 
Figure 1. Clinical Photographs A: Individual 1 at 5 years of age showing extreme 
microcephaly, as well as very small forehead and skull and upslanted palpebral fi ssures. 
B: Individual 2 at 13 years of age, showing microcephaly, prominent ears, drooling. C: 
Individual 3 at 6 years of age. Facial features included a sloping forehead, small chin, 
prominent nose, upward slant of the eyelid, prominent lower lip.
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Figure 2. Brain MRIs A-C Brain MRI Individual 1 performed at 5 years of age A: Sagittal 
T1 weighted view showing sloping forehead and fl attened occiput, grossly simplifi ed gyral 
pattern and normal cerebellum. Dysplasia of the corpus callosum is partially visible. Please 
note the extreme discrepancy between cerebral and cerebellar size compared to individual 
2 and 3. B: T2 weighted transverse view, showing simplifi ed gyration and moderately 
thickened cortex. C: Coronal FLAIR view showing occipital lobes smaller than cerebellar 
hemispheres. D-F Brain MRI of individual 2. D: Sagittal T1 weighted view showing sloping 
forehead, moderate simplifi ed gyral pattern, dysplastic corpus callosum and normal 
cerebellum. E: T2 weighted transverse view showing a moderately simplifi ed gyral pattern 
and moderately thickened cortex. F: T2 weighted coronal image again showing simplifi ed 
gyration and normal cerebellum. G-H: Brain MRI of individual 3. G: T1 weighted sagittal 
view showing microcephaly, normal corpus callosum and cerebellum; H:T2 weighted 
transverse view showing symmetrical polymicrogyria of temporal, parietal and frontal 
lobe with increased intra- and extracerebral space. I: T2 weighted coronal view showing 
polymicrogyric cortex and normal cerebellum. Remarkable in all three patients is the small 
anterior ventricle with a slightly enlarged posterior part of the ventricles.
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Results
The results of Sanger sequencing of WDR62 exons and intron-exon 
boundaries (Ensembl WDR62_201) in all three patients has been 
summarized in Table 1, together with all the mutations and phenotypes 
described in the literature. The mutations in three additional, previously 
undescribed patients are included. Patients 1 and 6 are homozygous for the 
mutation c.1605_1606insT resulting in a premature stop codon (p.Glu536*). 
Patients 2, 4 and 5 all have frame-shift mutations resulting in premature 
stop mutations. Patient 3 is homozygous for a missense mutation leading 
to a p.Arg863His substitution. Both parents of patient 3 were heterozygous 
for the change, which was predicted to be “probably deleterious” by the 
Polyphen2 and SNAP algorithms. This change is not reported in dbSNP 
databases nor in healthy individuals of the 1000 Genome Project. IER3IP1 
was sequenced in patient 3 because of the combination of microcephaly 
and childhood diabetes 14 and no mutation was found.
On routine Affymetrix GeneChip Human Mapping 250K SNP array performed 
on individual 1, copy number analysis indicated a duplication on chromosome 
17q25qter from base pair position 80559167-tel (hg 19; last SNP before 
duplication rs3794716) (fi gure 3) which contains 13 genes (Supplemental 
Table S1 and fi gure 3). The duplication was confi rmed by genomic quantitative 
PCR (qPCR) as being present in the proband and the asymptomatic 
mother. An overlapping duplication is described in the Toronto database of 
genomic variants (DGV) in one healthy individual. Within the duplicated area, 
tubulin cofactor D (TBCD) attracted our attention as the only gene possibly 
contributing to the phenotype (Supplementary table S1). TBCD is involved in 
microtubule assembly and disassembly and is essential for spindle microtubule 
dynamics15,16 which are crucial during cortical development. Mutations in 
tubulin subunit genes and genes encoding microtubule-associated proteins 
such as α-Tubulin 1A, LIS1 and DCX lead to lissencephaly or pachygyria 
due to aberrant neuronal migration16,17,18. Mutations in tubulin cofactors have 
been predicted to cause cortical malformations in humans19. As the MRI 
phenotype of individual 1 was rather reminiscent of pachygyria we decided 
to analyze TBCD in depth. On sequencing TBCD (Ensembl transcript 
TBCD_001) in the proband and the parents, a novel missense mutation in 
exon 35 was identifi ed, c.3361T>G, which results in an amino acid change 
from phenylalanine to valine (p.Phe1121Val) (fi gure 3). The change was 
absent in the mother, the father was heterozygous and it was present in the 
patient with an estimated ratio of 1/3 alleles, compatible with the presence of 
a duplicated wild-type allele (fi gure 3). 
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Figure 3. TBCD locus analysis Patient 1: CNV (proband and mother) on chromosome 17 
(yellow bar) with the genes within the duplication region. Underneath, Sanger sequencing 
showing a novel missense mutation in TBCD, c.3361T>G, in individual 1 at a ratio1/3, 
father who is heterozygote for the change and the mother (wild type). 
The p.Phe1121Val is predicted to be pathogenic by Polyphen-2 
and SNAP (supplemental data). This mutation was not found in 206 
chromosomes from ethnically matched individuals and is not reported 
in dbSNP130, nor in the 1000 Genome Project database, indicating 
a very low allele frequency. No difference in the levels of TBCD mRNA 
expression was detected by RT-qPCR between patient and control skin 
fi broblasts cultured under standard serum conditions (data not shown). 
We sequenced TBCD in individuals 2-6, including individual 6 who has 
the same WDR62 mutation (table 1) and a moderate phenotype: no 
mutation was found. To test whether biallelic TBCD mutations themselves 
are a frequent cause of cortical malformation, we sequenced twelve 
patients with micro-lissencephaly (Aix Marseille University, France) and 
no mutations in TBCD were found. We sequenced TBCD in an individual 
with mild intellectual disability and autistic features diagnosed at our 
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institution with a duplication on chromosome 17 including TBCD (bp 
78,456,063-78,774,742; hg19) detected on illuminaCytoSNP-12v2.1 
array, but no mutation was found. 
Discussion
The WDR62 mutation of patient 1 has not been previously described and 
is predicted to be a null allele. However this might not be suffi cient to 
explain the severe phenotype as patient 6 (same mutation), is ambulant 
and has some socialization skills. Moreover, other patients described with 
a null mutation do not have such a severe neurological presentation (table 
1)5,6,10.
In addition to the WDR62 mutation, patient 1 also has a change on both 
TBCD loci. It is possible, but not proven, that the severity in phenotype 
is due to the combination of WDR62 and TBCD mutations. However, it 
is not clear at the moment whether the combination of duplication and 
the missense has a deleterious effect. Considering that both heterozygote 
parents are healthy, it is possible that, if TBCD mutations were pathogenic, 
their inheritance would be recessive13. In that case, the phenotypic 
variability seen within the WDR62 spectrum could be explained by 
mutations in additional genes, such as TBCD 11. Alternatively, a single, 
heterozygote TBCD mutation could modify (and worsen) the effect of the 
WDR62 mutation. 
Mutations in tubulin genes (TUBA1A, TUBB2B, TUBB3, TUBB5, 
TUBA8) and tubulin-associated proteins (LIS1, DCX) are increasingly 
recognized to cause cortical malformation18,20. Assembly of alpha/beta 
tubulin heterodimers is under control of chaperone proteins collectively 
called tubulin cofactors A-D19. Tubulin cofactor D (TBCD) is not only 
an essential factor in assembly but, under control of ADP ribosylation 
factor-like 2 (ARL2), in disassembly of microtubules and therefore plays 
a central role in cell motility19,21. Unique among tubulin cofactors, TBCD 
is implicated in centriologenesis, spindle organisation, cell abscission 
and ciliogenesis, at a crossroad between cell division, cell migration 
and signaling15,16,21,22. TBCD is highly expressed in brain and spinal cord, 
during foetal development and therefore predicted that mutations in any 
of the tubulin cofactors could be linked to disorders of cell motility and 
possibly to malformations of the cerebral cortex19. As mentioned, WDR62 
protein is known to interact with mitotic spindles8,9,10. Its normal function 
might be strictly connected with a normal tubulin turnover. We did not 
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detect abnormal levels of TBCD mRNA in cultured fi broblasts; however 
a functional defect at the protein level cannot be excluded. Disruption of 
TBCD interaction can depend on subtle structural changes of interactors 
(as seen in TUBB5 mutations20) and both over and underexpression of 
TBCD are known to be deleterious16. Possibly, an abnormal assembly 
of microtubules in the presence of TBCD mutations interferes with 
centriologenesis and spindle formation by WDR62. However, the 
phenotypic abnormalities of the (biallelic) TBCD mutation alone are not 
at present predictable. 
The observation of the TBCD change was serendipitous in our patient 
because the array analysis was performed before the WDR62 mutations 
were identifi ed. However, molecular diagnosis of Mendelian traits is 
being replaced by targeted exome sequencing of panels of genes related 
to a specifi c phenotype23. If analysis of sequence variants remains 
limited to the known genes, the effect of non-allelic variants may go 
unnoticed. Triallelic and polygenic inheritance have been described 
in developmental disorders24. Our observation suggests that future 
application of exome sequencing to genetic diagnosis will require careful 
analysis of all detected variants for appropriate phenotype-genotype 
correlation predictions.
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Supplemental Material 
Clinical Reports
Individual 1: The proband’s antenatal history was uneventful apart from 
microcephaly revealed at 34 week scan. Her parents are consanguineous 
and of Turkish descent. An amniocentesis was performed which showed 
a normal karyotype. She was born by SVD at 38 weeks gestation with 
good APGAR scores. Her birth weight was 2.8kg and she was noted to 
be microcephalic (at age 3 weeks head circumference of 28.5 cm, -4SD) 
with an impalpable fontanelle, prominent occiput and extremely fl at 
frontoparietal skull. She was also hypotonic with an absent stepping refl ex. 
At 7 months, her head circumference -7 SD below expected, she was 
severely developmentally delayed and hypotonic with some movement of 
head and legs, but unable to roll. She was able to fi x, follow and smile 
sporadically. She developed epilepsy, which responded well to valproate. 
At 2 years HC was -9 SD below expected, she was noted to have 
dysmorphic features such as hypertelorism, upslanted palpebral fi ssures, 
large ears, broad thumbs and a short neck and severe psychomotor 
impairment (fi gure 1A). At age 5 years a MRI head revealed simplifi ed 
gyration, an apparently thickened cortex in the frontal areas, dysplastic 
corpus callosum with agenesis of the middle part and the splenium, normal 
myelination and normal cerebellum, compatible with a microcephaly 
agyria-pachygyria or microlissencephaly (fi gure 2A-C). By the age of 7 
years she had developed persistent crying, was exhibiting behavioural 
outbursts where she pulls hair, hits and bites. At the age of 13 years she 
has severe mental and motor impairment and epilepsy; she is unable to 
sit unsupported or to hold objects or speak, she reacts by smiling, can 
eat and chew and developed severe scoliosis. All metabolic and infective 
screens were negative. Ophthalmological examination was normal.
Individual 2: This boy presented with microcephaly at birth and developed 
in time ID and a spastic tetraparesis and epilepsy. At the age of 13 years 
he is able to sit unsupported, is cooperative and is interested in toys, drools 
and cannot speak but can communicate by gestures (fi gure 1B). He has 
epilepsy, which responded to valproate. His brain imaging at the age of 6 
years showed moderate simplifi ed gyration, moderately thickened cortex, 
dysplastic splenium of the corpus callosum, normal cerebellum. (fi gure 2D-F).
Individual 3: Female infant born to consanguineous parents from Tunisia 
after a pregnancy complicated by maternal diabetes which was diagnosed 
in the 3rd trimester controlled by diet. At birth, weight was 3750g and head 
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circumference as -3SD of expected. Early developmental milestones were 
achieved when assessed at 15 months and she has remained ambulant. 
Speech started at 4 years of age and was limited to a few words. She 
presented with diabetic keto acidosis at 6 years and has been on insulin 
since. A thorough clinical examination showed a normal height but head 
circumference -4SD below expected. Facial features included a sloping 
forehead, small chin, prominent nose, upward slant of the eyelid, 
prominent lower lip, profuse drooling. (fi gure 1C). Assessment of language 
and motor development indicated a general level between 2.5- 3.5 years. 
Neurologic examination showed mild asymmetric deep tendon refl exes, no 
neurolgical signs, mild hypotonia and valgus feet. EEG was normal. Brain 
MRI showed symmetric bilateral polymicrogyria extended to the temporal, 
parietal and frontal lobes, with incomplete opercularization of frontal and 
temporal lobes, no white matter abnormalities. Normal cerebellum, optic 
chiasma and nerves.(fi gure 2G-I) A CGH-array analysis and a karyotype 
are normal, except for several large regions of homozygosity.
Materials and Methods
SNP array and Copy Number detecti on
DNA was hybridized to the GeneChip Mapping 250K NspI array 
(Affymetrix) according to the standard protocol. Genotype data analysis 
and copynumber detection were performed in Affymetrix Genotyping 
Console v.4.1.1 using the BRLMM algorithm. The obtained .CEL and .CHP 
fi les were used for copynumber detection in CNAG v3.0.
Sequencing analysis
Amplifi cation reactions were performed in a total volume of 20 μl, containing 
1x PCR buffer with Mg (Roche), 200 μM of each dNTP, 1 μM forward 
primer, 1 μM reverse primer, 0.1 units Fast Start Taq DNA polymerase 
(Roche) and 25 ng genomic DNA. PCR conditions: 5’ 960C, 10 cycles of 
30’’ 960C, 30’’ 680C (-10C/cycle), 60’’ 720C, followed by 25 cycles of 30’’ 
960C, 30’’ 580C, 60’’ 720C and a fi nal extension for 5’ 720C.
PCR reactions were purifi ed with ExoSAP-IT (USB). Direct sequencing of 
both strands was performed using Big Dye Terminator chemistry ver. 3.1 
(Applied Biosystems). DNA fragment analysis was performed using capillary 
electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems) and 
the software package Seqscape (Applied Biosystems, version 2.1). 
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Supplemental Table (S1)
Genes in duplication region on chromosome 17 
Gene Gene Symbol Functi on
Forkhead box K2 FOXK2
Involved in regulati on of viral and 
cellular promoter elements, not 
expressed in brain.
WDR45-Like WDR45L Unknown, not expressed in brain
Hypotheti cal LOC728694 LOC728694 Unknown
RAB40B RAB40B
Member RAS oncogene family, not 
expressed in brain
Fructosamine 3 kinase related protein FN3KRP
Intermediate metabolism, 
putati vely involved in deglycati on of 
proteins
Fructosamine 3 kinase FN3K
Intermediate metabolism, 
deglycati on of proteins
Zinc fi nger protein 750 ZNF750 Related to seborrhea-like dermati ti s
Tubulin folding cofactor D TBCD
Involved in microtubule dynamics, 
highly expressed in (foetal) brain 
and spinal cord 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase-like
B3GNTL1 Unknown, not expressed in brain
Predicted LOC 644193 LOC644193 Unknown
Meteorin, glial cell diff erenti ati on 
regulator like
METRNL Unknown, not expressed in brain
(no longer annotated on chrom 17q25)
Similar to 60s ribosomal protein FLJ43681 Pseudogene, non coding RNA
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Figure S1. Protein Prediction Programme results for mutation c.3361T>G, in TBCD in 
Individual 1, also showing a snapshot of sequence conservation data generates by 
polyphen 2. This shows species conservation at amino acid position 1121 from  across 
species with Rhesus Macaque at the top to the Three Spined Stickleback (bottom of the 
table).
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SNAP analysis
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Discussion 
Increased apoptosis as a mechanism in primary 
microcephaly
Primary or congenital microcephaly with a normal brain structure or 
simplifi ed gyral pattern has long been thought to be the result of a decrease 
in the proliferation secondary to a reduction in the neuroprogenitor pool1. 
Programmed cell death or “apoptosis” is essential for normal brain 
development with the highest levels in the ventricular and subventricular 
zone2. This has been supported by animal studies, for example mice haplo 
insuffi cient for Magoh (Mos +/-) demonstrate a microcephaly secondary 
to an increase in neuronal apoptosis as well as a decrease in the 
neuroprogenitor population3. Magoh encodes an exon junction component 
which regulates neural stem cell division3. Conversely mice that are 
defi cient for pro-apoptotic genes (casp 9) show an increase in brain size4. 
In humans none of the known genes for primary microcephaly (MCPH) 
are thought to cause an increase in apoptosis, almost all of them encode 
for proteins that are components of centrosomes or mitotic spindle and 
thus postulated to cause microcephaly from a decrease in the progenitor 
pool5. This thesis describes the potential role of apoptosis in disorders 
presenting with a congenital or “primary” microcephaly.
Apoptosis or “programmed cell death” can occur in every cell in the body; it 
is under complex genetic control and ends with the cell undergoing distinct 
morphological changes. This includes the cell shrinking and condensing, 
the cytoskeleton collapsing, the nuclear envelope disassembling, the 
nuclear DNA breaking down and fi nally the cell surface alters allowing 
the cell to be phagocytosed without releasing any toxins and damaging 
surrounding cells6. 
Apoptosis occurs by activation of a multi-factorial pathway that ends in 
a caspase cascade. Every cell in the body contains pro-caspases which 
need to be cleaved in order to become active. There are two types of 
caspases, initiator caspases (caspase 2,8,9,10) and effector caspases 
(caspase 3,6,7). Initiator pro-caspases are activated by binding to an 
adaptor protein, these active initiator caspases then cleave the effector 
caspases downstream within moments which amplifi es the signal and 
causes cell death via the “caspase cascade”. Apoptosis can be triggered 
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by extracellular (extrinsic apoptosis) or intracellular (intrinsic apoptosis) 
pathways. These include the end point of DNA repair pathway or unfolded 
protein response (UPR) in intrinsic apoptosis or extra cellular pathways 
such as the TNF pathway for the extrinsic apoptosis. The end point for 
both is the caspase cascade. BCL-2 and IAP proteins are important for 
control of the caspase cascade and the infl uence is at many levels of the 
cascade, but are the essential mediators of the intrinsic apoptosis pathway 
(fi gure 1). 
Figure 1. Simplifi ed diagram of apoptotic pathways and showing the role of BCL-2 in all 3 
pathways. 
The intrinsic apoptosis pathway is considered to be essential in 
regulation of embryonic development and might be involved in the onset 
of microcephaly7,8. One of the intrinsic pathways leading to apoptosis 
is dependent on the endoplasmic reticulum (ER) unfolded protein 
response. Wolcott Rallison syndrome is a known example of apoptotic 
mechanism as cause of pancreatic and cerebral damage, caused by 
abnormal compensation of ER stress response9. We studied two families 
with an overlapping phenotype and we found mutations in immediate-
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early-response-3-interacting protein-1(IER3IP1) being causative of 
Microcephaly Epilepsy Diabetes (MEDs) syndrome. Using tests for 
apoptosis in fi broblasts and post mortem data, which showed increased 
apoptosis in the cortex and pancreas we found evidence which supported 
this mechanism. Unfortunately very little is known about IER3IP1 only 
that it potentially interacts with immediate early response-3 (IER3). Both 
the mutations we described are in the predicted ER transmembrane 
domain of IER3IP1 which could explain the increased apoptosis observed 
is secondary to an inappropriate unfolded-protein response. IER3IP1 
is reported to have a role in ceramide induced apoptosis10 and appears 
from previous publications11 and our experimental data to be under some 
control from TNF alpha. Thus this would place IER3IP1 in the caspase 
cascade. In support of this is in one individual harbouring an IER3IP1 
mutation we found a dysregulation of BCL-2 family, the anti-apoptotic BCL-
2 was down regulated by 120 fold and the pro-apoptotic BCL-2A1 was up 
regulated by approximately 3.7 fold (previously unpublished data) along 
with dysregulation of genes involved in the TNF pathway, possibly placing 
IER3IP1 in both the extrinsic and intrinsic apoptotic pathway. (Table 1) 
Table 1. Results of human apoptosis RT-pcr expression array (SABiosciences RT² Profi ler 
PCR Arrays) showing dysregulation of apoptotic genes in patient 1 harbouring an IER3IP1 
mutation.
Gene Fold up regulati on Gene Fold down regulati on
X1AP 12.1 BCL.5-2 120.6
BNIP 4.4 CD40L 16
DAPK1 19.64 TRAF3 9.9
BCL2A1 3.7 TRAF4 17.7
TNFRSF11B 4.2
TP53 125.8
The results from chapter 2 prompted a look to other disorders where 
primary microcephaly is a key feature with the possibility of apoptosis 
being a mechanism. This would include DNA repair disorders, in which 
microcephaly is an inconsistent feature12. Apoptosis versus degeneration 
of neural cells has been proposed as to why some DNA repair disorders 
present with microcephaly and others with brain atrophy and this is 
thought to be dependent on activation of the ATM/ATR pathway12. 
Individuals with Cerebro-Oculo-Facial-Skeletal (COFS) syndrome present 
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with severe congenital microcephaly, cataracts or microphthalmia, facial 
dysmorphism and arthrogryposis13. Brain MRI usually shows microcephaly 
with a simplifi ed gyral pattern of the cerebral cortex, enlarged lateral 
ventricles and delayed myelination14. Individuals usually have severe 
neurodevelopmental delay and die in infancy secondary to brain stem 
dysfunction13. We tested several individuals who presented with COFS 
syndrome due to a mutation in ERCC5 (XPG complementation group) for 
susceptibility to apoptosis and found a correlation between individuals who 
present with a prenatal onset of microcephaly and increased susceptibility 
of fi broblasts to apoptosis. Along with mouse studies of Ercc5 knockout 
mice which showed a signifi cant increase in apoptosis at week 4 of life in 
the cerebral cortex and have a phenotype of primary microcephaly with 
growth retardation. This provides circumstantial evidence for an increase 
in apoptosis being causative of primary microcephaly in COFS syndrome. 
Since microcephaly and growth retardation already occurs before birth, 
the most likely explanation of these abnormalities is the dysregulation 
of intrinsic developmental apoptosis. However, it is also possible that 
extrinsic apoptotic triggers play a role in disease progression and 
neurodegeneration. 
ERCC5 is important in the DNA repair pathway and is responsible for the 
3`incision in Nucleotide Excision Repair (NER) via the transcription coupled 
repair pathway (TCR). ERCC5 directly interacts with the other xeroderma 
pigmentosum-related (XP) proteins such as ERCC1 and ERCC4 which have 
been described as causative of COFS15. The NER pathway is important 
excision pathway for removing mutations derived from UV damage and 
protecting from cancer. The NER pathway is also postulated to have a role 
in repair outside the spectrum of UV damage as is evident by mutations 
in genes encoding proteins important in this pathway have a neurological 
phenotype16. ERCC5 may also have a role in base excision repair which 
has a role in repairing DNA damage after oxidative damage17. It has been 
proposed that severe mutations such as these seen in our COFS patients 
result in a neurological phenotype due to the defect in oxidative cell damage 
repair and substitutions result in a XP phenotype due to NER defect. Neurons 
are particularly susceptible to oxidative damage and accumulation of lesions 
leading to cell death could explain the progressive neurological phenotype 
exhibited by some patients18. 
ERCC5 has been reported to have a role as a negative regulator of 
apoptosis and this could be via the BCL proteins. BCL-X is one of the 
negative regulators of apoptosis and a key regulator in mammalian 
brain development19 and it has been shown patient cells with ERCC5 
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null mutations have decreased levels of BCL-X, which would explain the 
increased sensitivity to apoptosis in patient cells20.
Individuals with PNKP mutations, another DNA repair disorder described 
in chapter 3, also present with congenital microcephaly. This was original 
described by Shen et al as an epileptic encephalopathy syndrome (MCSZ), 
in individuals with microcephaly, intractable seizures and developmental 
delay21. We used whole genome sequencing (WGS) to explain the 
phenotype in our family to include primary microcephaly, intellectual 
disability, progressive cerebellar atrophy, severe polyneuropathy and 
seizures and, surprisingly, discovered a previously described homozygous 
mutation. PNKP is involved in single strand break (SSB) DNA repair by 
binding to a scaffold provided by XRCC1 and processes the repaired 
strands for the DNA ligase LIG322,23. PNKP interacts with aprataxin protein, 
APTX (mutated in ataxia-oculomotor apraxia type 1) and with tyrosyl-DNA 
phosphodiesterase TDP1, which is mutated in spino-cerebellar ataxia - 
neuropathy type 1 (SCAN-1) which has a phenotypic overlap with our 
family24. This knowledge together with information from the animal models, 
(XRCC1 KO mice show loss of cerebellar purkinje cells, ataxia and 
seizures25) can help to explain the cerebellar changes and neuropathy in our 
family. However, these additional phenotypes did not explain the congenital 
microcephaly seen in our patients and the patients described by Shen at 
al21. PNKP is also involved in the repair double strand break (DSB) related 
to non-homologus end joining (NHEJ) occurring during mitosis23. DSB is 
particularly important in dividing cells during development. In this pathway 
PNKP directly interacts (via the third fork head domain) with the scaffold 
XRCC4 and activates LIG4 (mutations cause severe immune defi ciency 
with microcephaly)23. PNKP is activated and recruited by ATM and ATR 
which are associated with ataxia-telangiectasia and Seckel syndrome 
(primary microcephaly and primordial dwarfi sm) respectively. DNA ligase 
4 (Lig4) knock out mice show increased apoptosis throughout the nervous 
system and die in the embryonic period. Lig4 cerebral conditional KO mice 
(Lig4 Nes-Cre) have a pronounced microcephaly and show increased 
apoptosis from E13.5, peaking at E15 via an ATM dependent and an ATM 
independent process26. Additionally PNKP interacts directly with ERCC4 
to activate Lig427. This could be used to predict that humans with the 
PNKP mutations would also exhibit a profound congenital microcephaly 
secondary to apoptosis during the developmental period. This had not 
been shown in humans in the original study21. In support of this hypothesis 
we did see an increased susceptibility to apoptosis in fi broblasts from 
individuals with PNKP mutation in comparison to controls. 
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Although it appears that the MCPH genes and the DNA repair genes are 
completely separate causes of microcephaly there is a link via MCPH1. 
MCPH1 was the fi rst primary microcephaly gene identifi ed and is 
associated with a small brain with a normal cortical architecture28. MCPH1 
contains 3 BRCT (breast cancer C-terminal) motifs which are commonly 
found in DNA damage response proteins in order to ensure effi cient cell 
cycle checkpoint arrest after DNA damage28. MCPH1 can modulate both 
the ATM and ATR repair pathway and its absence means that numerous 
proteins associated with the pathway fails to co-localise29,30. Interestingly 
disorders that are due to a defective ATR pathway (Seckel syndrome) also 
show microcephaly as a predominant feature.
It does appear that although apoptosis occurs in every cell type in the body, 
increased susceptibility to apoptosis results in a neurological phenotype. 
This is probably due to a combination of factors including differences in gene 
expression in different tissues and the susceptibilty of developing neurons to 
apoptosis. In the cases described in chapter 2, IER3IP1 mutations result in 
a phenotype of MSG and diabetes, IER3IP1 has a higher expression in the brain 
and pancreas therefore explaining this phenotype. DNA repair is important in all 
cells, but neurons appear to be particularly susceptible to damage, particularly 
oxidative damage and this could explain the predominance for a neurological 
phenotype as described in chapter 3. In summary, we have reviewed several 
distinct disorders where primary microcephaly appears to be related to 
increase in apoptosis in neurons in the pre-natal period, underscoring the 
primary role of apoptosis in brain development. DNA repair pathways and ER 
stress response appear to be key regulators of this pathway. 
Potential for Prevention and Therapeutic Interventions
In chapter 4 we have described a patient with extreme microcephaly 
and changes at two loci. The fi rst is WDR62, which is the MCPH2 gene 
related to primary microcephaly. The second TBCD has not been related 
to human disease. Based on the type of changes we observed in TBCD 
we cannot conclude whether there is a gain or loss of function. As over 
and under expression of TBCD has been shown to cause defect in 
microtubules31, probably developmental defects could result from either. 
The putative involvement of TBCD raises interesting questions about 
potential intervention.
There is a link between primary microcephaly proteins and other diseases, 
specifi cally cancer. Cancer can be described as a disorder of proliferation 
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which requires increased mitosis and rapid turnover of the mitotic spindle 
or a decrease in apoptosis causing an overgrowth. Primary microcephaly 
proteins have been suggested as potential targets for cancer therapy 
because almost all of the genes encode for proteins involved in centrosome 
or mitotic spindle function. Disrupted spindle function is a target of some anti 
tumour drugs such as vinblastine and paclitaxel which are specifi c tubulin 
binding agents. These work to promote disassembly of the microtubule 
and arrest cell division32,33. Bisphosphonates are trialled against breast 
cancer work by causing up regulation of TBCB and cause disruption 
of microtubules34. So potentially other tubulin folding cofactors such as 
TBCD could be an antitumor target. This has the advantage of being 
tubulin specifi c and upregulation could cause microtubule release from 
the centrosome and G1 arrest34, thus halting uncontrolled proliferation in 
cancer cells. Eventually pharmacological modulation of TBCD might also 
have an effect on individuals with primary microcephaly. 
MCPH genes have been shown to be up regulated in cancer cell lines. 
ASPM (MCPH5) expression is increased in uterine and ovarian cancer cell 
lines when compared to normal tissue35. STIL (MCPH7) is upregulated in 
many cancer cell lines36. Decreasing the expression of STIL in a cancer 
cell line leads to increased apoptosis of the cancer cells secondary 
to delayed Cdk1 activation, which leads to the suggestion of STIL as 
a potential cancer target36. Potentially, as the gene mutations we have 
described lead to increased apoptosis, it could theoretically be possible to 
manipulate expression and induce apoptosis in cancer cell lines. It would 
be interesting to explore if incidence of cancer is lower in MCPH patients, 
as it has been suggested by anecdotal reports37. 
Brain damage by hypoxic insult either in neonatal hypoxic encephalopathy 
or by ischemic stroke occurs via an increase in apoptosis of neurons causing 
lasting and irreversible consequences. In neonatal hypoxic ischemic 
encephalopathy (HIE), the neonatal brain is sensitive to undergoing 
apoptosis and occurs days after the initial insult38. Rat models of HIE have 
shown high levels of caspase 3 that remain elevated for seven days after 
the initial injury39. Apoptosis has a prolonged role in the neurodegeneration 
after hypoxic ischemia in the newborn rat39. Anti-apoptotic gene BCL-2 
has been suggested as a potential therapeutic target for neonatal HIE 
and there have been reports of animal experiments using adenovirus 
vectors to increase BCL-2 expression and thus decrease apoptosis both 
via caspase dependent and caspase independent pathways38. In view of 
our data generated showing decreased BCL-2 expression in our individual 
with an IER3IP1 mutation (table 1) this would worth exploring to see if the 
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disease process could be arrested by increasing BCL-2 expression and 
possibly give some symptomatic relief for the seizures, neurodegeneration 
and in the case of IER3IP1, the diabetes which was diffi cult to control. 
Concluding remarks
Since the human genome sequencing project (HGP) was completed in 
2001 there has been rapid and continuous development in sequencing 
techniques, from Sanger sequencing that was developed in the 1970s to 
genomic SNP-based microarrays, to whole exome sequencing (WES) and 
whole genome sequencing (WGS) or “next generation sequencing”. It is 
now possible to sequence the whole genome of an individual in a few days. 
The use of this ‘state of the art’ technology for genome analysis presented 
in this thesis has led to important conclusions. We have identifi ed the cause 
of a severe congenital microcephaly in IER3IP1 mutations and, together 
with the observations in DNA repair syndromes with microcephaly, we 
confi rmed the assumption that apoptosis can play a major role in the onset 
primary microcephaly. The use of even more advanced and unbiased 
technologies, such as WGS, has also led to two additional conclusions. First 
we identifi ed a new phenotype linked to a known gene for microcephaly 
(PNKP, see chapter 3). Secondly, we identifi ed a second gene, TBCD, as 
potential modifi er of a phenotypic variable disorder such as WDR62-related 
microcephaly. Both these observation are paradigmatic to what the future 
of genetic analysis for rare Mendelian disorders will be regarding the use 
of such techniques. We may be able to diagnose new disorders caused 
by mutations in known genes and we may fi nd additional mutations in the 
same individual that contribute and modulate the phenotype. However, 
a challenge will be to identify which mutations are clinically relevant. This 
will involve laboratory, animal and possibly stem cell research and this 
information may change over time. The concept that NGS is a “one time” 
test is probably misleading. Due to the rapid discovery of disease causing 
mutations the data generated from an individual could need to be re-
analysed regularly depending on recent discoveries. This then brings up 
both ethical and practical questions of where the data should be stored 
and who should have access to it? These questions need to be addressed 
before we can use WGS regularly in a clinical diagnostic setting.
 It is certain that medical specialists in several disciplines will need to 
be familiar with new techniques such as whole genome sequencing and 
collaborate with the clinical geneticists and basic scientists to further identify 
genes responsible andincrease our understanding of brain development 
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and disease processes. We then need to use this knowledge to perform 
translational research that can provide direct benefi t to the individuals and 
families affected. In fi nding the genes responsible we can help to give the 
families some understanding, as the disease processes in the individuals 
described are unrelenting and lead to an early death. We can also offer 
prenatal testing, if the family requires it. As these diseases are rare and 
therefore the numbers of affected individuals are small, knowledge and 
multi-disciplinary skill base should be concentrated in specialized centres 
with scientifi c interest so that the insight into disease mechanisms creates 
new possibilities for intervention. 
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Summary
Chapter 1, the introduction describes the defi nition of microcephaly, a brief 
overview of potential role of microcephaly genes in evolution and a summary 
of current knowledge of genetic caused of congenital microcephaly. 
Chapter 2 describes two families whose children were affected by a combination 
of microcephaly, epilepsy, neonatal diabetes and early death. By using 
homozygosity mapping and linkage analysis we identify homozygous IER3IP1 
mutations in the affected individuals from both families. Using evidence from 
post mortem data and from fi broblasts from an affected individual we show 
a link between increased susceptibility to apoptosis and description of a new 
syndrome Microcephaly, Epilepsy and Diabetes (MEDs, OMIM 614231). 
Chapter 3 is focused on the link between DNA repair disorders and 
microcephaly. In chapter 3.1 we use whole genome sequencing to identify 
PNKP mutations in a family causing a combination of primary microcephaly, 
progressive polyneuropathy, severe progressive cerebellar atrophy, mild 
epilepsy and intellectual disability which expanded the known phenotype. 
We showed that patient cells have an increased tendency to apoptosis 
under stress conditions which could help to explain the microcephalic 
phenotype. These fi ndings led us to look at other DNA repair disorders 
that present with a primary microcephaly in order to explore a potential 
link between apoptosis and microcephaly. In chapter 3.2 we describe the 
clinical presentation and studied the tendency to apoptosis in fi broblasts 
derived from eight individuals bearing ERCC5 (XPG) mutations with 
variable presentation, ranging from mild neurologic symptoms to severe 
microcephaly and death in early infancy and one Cockayne syndrome 
patient. We found that apoptotic levels correlated with the severity of 
microcephaly and disease course. This link was supported by data from 
Ercc5 knock-out mice which showed increased apoptosis at 4 weeks in 
tissues including frontal cortex.
Chapter 4 describes individuals with WDR62 mutations and one 
severely affected individual who as well as a homozygous mutation in 
WDR62, has duplication on chromosome 17 and a predicted pathogenic 
mutation in tubulin co-factor D (TBCD). We explore the potential role 
as a phenotypic modifi er of TBCD and the potential role of polygenetic 
inheritance in the presentation of microcephaly associated with cortical 
malformations. 
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The thesis ends at chapter 5, the discussion with an overview of our 
fi ndings and possible future developments. We have showed a link 
between apoptosis and microcephaly in human disease and discuss the 
relevance in the clinical setting including future possible interventions. 
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Samenvatting
Hoofdstuk 1, de introductie, beschrijft de defi nitie van microcefalie, een 
kort overzicht van de potentiële rol van microcefalie genen in de evolutie 
en een samenvatting van de huidige kennis van genetische oorzaken van 
aangeboren microcefalie.
In hoofdstuk 2 worden 2 families beschreven, waarvan de kinderen 
een combinatie hebben van microcefalie, epilepsie, neonatale diabetes 
en vroegtijdig overlijden. Met behulp van homozygotie mapping en 
koppelingsonderzoek zijn homozygote IER3IP1 mutaties gevonden in de 
aangedane individuen van beide familes. Met behulp van bewijs verkregen 
uit post mortem bevindingen en fi broblasten van een aangedaan individu 
konden we een verband beschrijven tussen een verhoogde vatbaarheid voor 
apoptose en microcephalie. Dit werk heeft geleidt tot de beschrijving van een 
nieuw syndroom: Microcefalie, Epilepsie en Diabetes (MED, OMIM 614231).
Hoofdstuk 3 is gericht op het verband tussen DNA repair aandoeningen 
en microcefalie. In hoofdstuk 3.1 beschrijven we het gebruik van whole 
genome sequencing om PNKP mutaties te identifi ceren in een familie met een 
combinatie van primaire microcefalie, progressieve polyneuropathie, ernstige 
progressieve cerebellaire atrofi e, milde epilepsie en intelectual disability , 
wat heeft geleid tot een uitbreiding van het reeds beschreven fenotype. We 
hebben laten zien dat fi broblasten van patiënten een verhoogde vatbaarheid 
voor apoptose hebben onder stress- omstandigheden, dat kan helpen om het 
fenotype met microcephalie te verklaren. Dit was voor ons de aanleiding om 
andere DNA repair aandoeningen te bestuderen die zich presenteren met een 
primaire microcefalie, om zo een potentiëel verband te leggen tussen apoptose 
en microcefalie. In hoofdstuk 3.2 beschrijven we de klinische presentatie en 
bestudeerden we de vatbaarheid voor apoptose in fi broblasten verkregen 
van acht individuen met ERCC5 (XPG) mutaties met variabele presentatie, 
variërend van milde neurologische symptomen tot ernstige microcefalie en 
overlijden op vroege kinderleeftijd en een patiënt met Cockayne syndroom. We 
vonden dat de mate van apoptose correleerde met de ernst van de microcefalie 
en het ziekteverloop. Dit verband werd ondersteund door beschrijvingen van 
Ercc5 knock-out muizen, die op de leeftijd van 4 weken verhoogde apoptose 
laten zien in weefsel, waaronder de frontale cortex.
Hoofdstuk 4 beschrijft individuen met WDR62 mutaties en een ernstig 
aangedaan individu met een homozygote mutatie in WDR62, met een 
duplicatie op chromosoom 17 en een mutatie, voorspeld als pathogeen, in 
tubulin co-factor D (TBCD). We onderzoeken de mogelijke rol van TBCD 
 Addendum164  
als een modulator van het fenotype en de potentiële rol van polygenetische 
overerving in de presentatie van microcefalie geassocieerd met corticale 
malformaties.
Het proefschift eindigt met hoofdstuk 5, de discussie, met een overzicht 
van onze bevindingen en mogelijke toekomstige ontwikkelingen. We hebben 
een verband laten zien tussen apoptose en microcephalie in humane ziekte 
en bespreken de relevantie voor de klinische setting, inclusief mogelijke 
behandelingsopties in de toekomst.
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List of Abbreviations
AD  Autosommal Dominant 
AR  Autosommal Recessive
BRCT  Breast cancer susceptibility protein C-terminal
CMV  Cytomegalovirus
CNS  Central Nervous System
CNV  Copy Number Variation
COFS  Cerebro-Ocular-Facial- Skeletal
CS  Cockayne Syndrome
CSF  Cerebrospinal fl uid
CT  Computerised Tomography
DNA  Deoxyribonucleic acid
DSB  Double Stranded Break
DTT  Dithiothreitol
EEG  Electroencephalograph
EMG  Electromyogram
ER  Endoplasmic Reticulum
HIV  Human Immunodefi ciency Virus
HMSN  Hereditary Motor Sensory Neuropathy
ID  Intellectual Disability
LMD  London Medical Database
LOH  Loss of Heterozygosity
MCPH  Microcephaly Primary
MC+PMG Microcephaly and Polymicrogyria
MEF  Mouse Embryonic Fibroblasts
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MLIS  Microcephaly and Lissencephaly
MRI  Magnetic Resonance Imaging
MSG  Microcephaly Simplifi ed Gyration
MTOC  Microtubule Organising Centre
NER  Nucleotide Excision Repair
OFC  Occipito Frontal Circumference
PCH  Ponto-Cerebellar Hypoplasia
PCM  Pericentriolar Material
PKU  Phenyl Ketonuria
PND  Permanent Neonatal Diabetes
RNA  Ribonucleic Acid
SD  Standard Deviation
SNP  Single Nucleotide Polymorphism
SSB  Single Stranded Break
TCR  Transcription Coupled Repair
TNF  Tumour Necrosis Factor
TUNEL TdT-mediated dUTP Nick-End Labeling
UPR  Unfolded Protein Response
UV  Ultraviolet
WES  Whole Exome Sequencing
WGS  Whole Genome Sequencing
WRS  Wolcott Rallison Syndrome
XP  Xeroderma Pigmentosum
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Workload
(ECTS)
General courses 
– Classical Methods for Data-Analysis
– Molecular and Cell Biology
– SNPs and Human Disease
2011
2009
2008
5.7 ECTS
6 ECTS
1 ECTS
Specifi c courses
– Biomedical Research Techniques
– From Development to Disease
– Biomedical Research Techniques
– SPSS: Stati sti c Course for Novices
– Advanced Paediatric Life Support
– BPNA Epilepsy Training Level 2
2008
2009
2009
2009
2012
2012
1.5 ECTS
1.5 ECTS
0.8ECTS
1.5ECTS
1 ECTS
1 ECTS
Seminars and Workshops
– Ensemble Workshop
– Workshop on Photoshop and Illustrator CS4
– PhD Career Day
– Parti cipated in working group at European 
Research Conference on Paediatric 
Neurology, Tubingen
2008
2010
2011
2008
0.8 ECTS
0.3 ECTS
1 ECTS
Presentati ons
– In the department (2/year)
– CHD group weekly meeti ngs
2008-2013
2008-2013
(Inter) Nati onal Conferences
– Geneti ca Retraite, Rolduc, (oral presentati on)
– 14th Congress of the European Federati on of 
Neurological Societi es, oral presentati on and 
winner of “Young Neurologist of the year
– European Human Geneti cs Conference, 
Amsterdam (oral presentati on)
– Netherlands Human Geneti c Society 
Conference (oral presentati on)
– European Society of Magneti c Resonance in 
Neuropaediatrics (oral presentati on)
– Netherlands Paediatric Neurology Society 
2012 (oral presentati on)
2009
2010
2011
2011
2011
2012
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
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Others
– Clinical Geneti cs work discussion
– Group weekly meeti ngs
2009-2013
2009-2013
200
400
2. Teaching/Supervising
– Teaching Medical Students
– Mentoring Junior Doctors
2011-2012
2011-2012
1 ECTS
1 ECTS
Total 31.1 ECTS
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